Benutzer:Crazy-Chemist/Werkstatt
Zur Navigation springen
Zur Suche springen
<ref name="pmid20824145">{{cite journal |author=Steensland P, Simms JA, Nielsen CK, Holgate J, Bito-Onon JJ, Bartlett SE |title=The neurokinin 1 receptor antagonist, ezlopitant, reduces appetitive responding for sucrose and ethanol |journal=Plos One |volume=5 |issue=9 |pages= |year=2010 |pmid=20824145 |pmc=2931709 |accessdate=2011-01-15}}</ref>
<ref name="pmid17986694">{{cite journal |author=McMurray JJ, Teerlink JR, Cotter G, ''et al.'' |title=Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials |journal=[[Journal of the American Medical Association|JAMA: The Journal of the American Medical Association]] |volume=298 |issue=17 |pages=2009–2019 |year=2007 |month=November |pmid=17986694 |url=http://jama.ama-assn.org/cgi/content/full/298/17/2009 |accessdate=2010-11-05}}</ref>
<ref name="pmid15542526">{{cite journal |author=Urbanowicz W, Sogni P, Moreau R, ''et al.'' |title=Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats |journal=Gut |volume=53 |issue=12 |pages=1844–1849 |year=2004 |month=December |pmid=15542526 |pmc=1774327 |accessdate=2010-11-05}}</ref>
{{Internetquelle |url=http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20-430S003_Orgaran_prntlbl.pdf |titel=Full label information for ORGARAN™ (Danaparoid-Sodium) |hrsg=[[Food and Drug Administration]] |datum=2001-06-26 |seiten=18 |abruf=2010-10-05 |format=PDF (566 kB) |sprache=en}}
Danaparoid-Natrium
Definition
Zubereitung aus Natrium-Salzen einer Mischung von sulfatierten Glucosaminglycanen, die in Geweben von Schweinen vorkommen
Die Hauptkomponenten sind Heparansulfat und Dermatansulfat.
Bei vollständiger Hydrolyse werden D-Glucosamin, D-Galactosamin, D-Glucuronsäure, L-Iduronsäure, Essigsäure und Schwefelsäure freigesetzt. Die
Substanz hat die charakteristische Eigenschaft, die Inaktivierung von aktiviertem Blutgerinnungsfaktor X (Faktor Xa) durch Antithrombin zu fördern. Ihre Auswirkung
auf die Inaktivierung von Thrombin durch Antithrombin ist vernachlässigbar. Aktivität: 11,0 bis 17,0 Anti-Faktor-Xa-Einheiten je Milligramm (getrocknete Substanz). Ph. Eur. 6. Ausgabe, Grundwerk 2008
{{Gesundheitsinformation.de|http://www.gesundheitsinformation.de/alzheimer-demenz-wie-gut-helfen-cholinesterasehemmer.511.html|Alzheimer Demenz: Wie gut helfen Cholinesterasehemmer}}
[[doi:10.1073/pnas.1009396107]]
{{ISSN|1381-6128}}
<ref>{{cite journal |author=Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H |title=Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials |journal=BMJ (Clinical Research Ed.) |volume=331 |issue=7512 |pages=321–327 |year=2005 |month=August |pmid=16081444 |pmc=1183129 |accessdate=2010-10-06}}</ref>
{{cite journal |last= |first= |author= |authorlink= |coauthors= |editor1-first= |editor1-last= |editor1-link= |date= |year= |month= |title= |trans_title= |journal= |volume= |series= |issue= |page= |pages= |at= |publisher= |location= |issn= |pmid= |pmc= |doi= |bibcode= |oclc= |id= |url= |language= |format= |archiveurl= |archivedate= |accessdate= |laysummary= |laysource= |laydate= |quote= |ref= |separator= |postscript= }}
<ref>{{cite journal |author=Molly J. Crocketta, ''et al.'' |year=2010 |month=September |title=Serotonin selectively influences moral judgment and behavior through effects on harm aversion — PNAS |journal=PNAS Early Edition |volume=107 |issue=39 |pages=1–6 |url=http://www.pnas.org/content/early/2010/09/17/1009396107.full.pdf |doi=10.1073/pnas.1009396107 |accessdate=2010-09-29}}</ref>
* {{cite journal |author=Morgenstern LB, Demchuk AM, Kim DH, Frankowski RF, Grotta JC |title=Rebleeding leads to poor outcome in ultra-early craniotomy for intracerebral hemorrhage |journal=Neurology |volume=56 |issue=10 |pages=1294–1299 |year=2001 |month=May |pmid=11376176 |url=http://www.neurology.org/cgi/content/full/56/10/1294 |accessdate=2010-09-27}}
<ref name="pmid18765544">{{cite journal |author=Hou J, Wang D, Zhang R, Wang H |title=Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action |journal=Clinical Cancer Research : an Official Journal of the American Association for Cancer Research |volume=14 |issue=17 |pages=5519–5530 |year=2008 |month=September |pmid=18765544 |url=http://clincancerres.aacrjournals.org/content/14/17/5519.full.pdf+html |accessdate=2010-09-27}}</ref>
<ref name="pmid18752857">{{cite journal |author=Krishna S, Bustamante L, Haynes RK, Staines HM |title=Artemisinins: their growing importance in medicine |journal=Trends in Pharmacological Sciences |volume=29 |issue=10 |pages=520–527 |year=2008 |month=October |pmid=18752857 |pmc=2758403 |accessdate=2010-09-27}}</ref>
<ref name="pmid12481201">{{cite journal |author=David R. P. Guay |title=Update on fenofibrate |journal=Cardiovascular Drug Reviews |volume=20 |issue=4 |pages=281–302 |year=2002 |pmid=12481201 |url=http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3466.2002.tb00098.x/pdf |accessdate=2010-09-27}}</ref>
* {{cite journal |author=Chadwick LR, Pauli GF, Farnsworth NR |title=The pharmacognosy of Humulus lupulus L. (hops) with an emphasis on estrogenic properties |journal=Phytomedicine : International Journal of Phytotherapy and Phytopharmacology |volume=13 |issue=1–2 |pages=119–131 |year=2006 |month=January |pmid=16360942 |pmc=1852439}}
* {{cite journal |author=Overk CR, Guo J, Chadwick LR, ''et al.'' |title=In vivo estrogenic comparisons of Trifolium pratense (red clover) Humulus lupulus (hops), and the pure compounds isoxanthohumol and 8-prenylnaringenin |journal=Chemico-biological Interactions |volume=176 |issue=1 |pages=30–39 |year=2008 |month=October |pmid=18619951 |pmc=2574795}}
* {{cite journal |author=Koo JH, Kim HT, Yoon HY, ''et al.'' |title=Effect of xanthohumol on melanogenesis in B16 melanoma cells |journal=Experimental & Molecular Medicine |volume=40 |issue=3 |pages=313–319 |year=2008 |month=June |pmid=18587269 |pmc=2679287}}
* {{cite web |url=http://epub.uni-regensburg.de/12363/1/DISSERTATION_Christoph_Dorn.pdf |title=ANALYSIS OF THE EFFECTS OF XANTHOHUMOL ON HEPATIC HOMEOSTASIS, INFLAMMATION, FIBROSIS AND CANCEROGENESIS |author=Christoph Michael Dorn |date=2009 |format=pdf |work=Inaugural-Dissertation |publisher=FAKULTÄT CHEMIE UND PHARMAZIE DER UNIVERSITÄT REGENSBURG |pages=152|accessdate=2010-09-25}}
<ref name="pmid12481418">{{cite journal |author=Gerhauser C, Alt A, Heiss E, ''et al.'' |title=Cancer chemopreventive activity of Xanthohumol, a natural product derived from hop |journal=Molecular Cancer Therapeutics |volume=1 |issue=11 |pages=959–969 |year=2002 |month=September |pmid=12481418 |url=http://mct.aacrjournals.org/content/1/11/959.full.pdf |accessdate=2010-09-25}}</ref>
Der Wirkstoff Artesunat wurde 2002 von der [[Weltgesundheitsorganisation]] (WHO) in die [[Liste der unentbehrlichen Arzneimittel der Weltgesundheitsorganisation]] aufgenommen.<ref>[http://apps.who.int/emlib/MedicineDisplay.aspx?Language=EN&MedIDName=28%40artesunate ''Artesunat WHO Model Lists of Essential Medicines''], abgerufen am 26. September 2010.</ref>
Der Wirkstoff Allopurinol wurde 1977 von der [[Weltgesundheitsorganisation]] (WHO) in die [[Liste der unentbehrlichen Arzneimittel der Weltgesundheitsorganisation]] aufgenommen.<ref>[http://apps.who.int/emlib/MedicineDisplay.aspx?Language=EN&MedIDName=14%40allopurinol ''Allopurinol WHO Model Lists of Essential Medicines''], abgerufen am 16. August 2010.</ref>
<ref>{{cite journal |author=Byakika-Kibwika P, Lamorde M, ''et al.'' |title=Update on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria |journal=Therapeutics and Clinical Risk Management |volume=6 |issue= |pages=11–20 |year=2010 |pmid=20169032 |pmc=2817784 |accessdate=2010-09-23}}</ref>
<ref>{{cite journal |author=Ro DK, Paradise EM, Ouellet M, ''et al.'' |title=Production of the antimalarial drug precursor artemisinic acid in engineered yeast |journal=[[Nature]] |volume=440 |issue=7086 |pages=940–943 |year=2006 |month=April |pmid=16612385 |doi=10.1038/nature04640 |accessdate=2010-09-23}}</ref>
<ref name="WHO">{{cite book |author= |authorlink= |editor= |others= |title=Guidelines for the Treatment of Malaria (Nonseral Publication) |edition=2nd. |language=en |publisher=World Health Organization |location=Geneva |year=2010 |origyear= |pages= |quote= |isbn=978-92-4-154792-5 |url=http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf |accessdate=2010-09-23 }}</ref>
* {{cite journal |author=Palanichamy K, Kaliappan KP |title=Discovery and syntheses of "superbug challengers"-platensimycin and platencin |journal=Chemistry, an Asian Journal |volume=5 |issue=4 |pages=668–703 |year=2010 |month=April |pmid=20209576 |url=http://onlinelibrary.wiley.com/doi/10.1002/asia.200900423/pdf}}
* {{cite journal |author=Volz HP, Gleiter CH |title=Monoamine oxidase inhibitors. A perspective on their use in the elderly |journal=Drugs & Aging |volume=13 |issue=5 |pages=341–355 |year=1998 |month=November |pmid=9829163 }}
* {{cite journal |author=Fiedorowicz JG, Swartz KL |title=The role of monoamine oxidase inhibitors in current psychiatric practice |journal=Journal of Psychiatric Practice |volume=10 |issue=4 |pages=239–248 |year=2004 |month=July |pmid=15552546 |pmc=2075358 }}
* {{cite web |url=http://www.justice.gov/dea/programs/forensicsci/microgram/journal2010/mj7-1_12-15.pdf |title=The Characterization of 3,4-Methylenedioxypyrovalerone (MDPV) |author=Joshua C. Yohannan* and Joseph S. Bozenko, Jr. |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote= |accessdate=}}
Microgram Journal, Volume 7, Number 1 (March 2010)
* {{cite journal |author=Meltzer PC, Butler D, Deschamps JR, Madras BK |title=1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors |journal=Journal of Medicinal Chemistry |volume=49 |issue=4 |pages=1420–1432 |year=2006 |month=February |pmid=16480278 |pmc=2602954}}
* {{cite journal |author=Cuchel M, Bloedon LT, Szapary PO, ''et al.'' |title=Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia |journal=[[The New England Journal of Medicine]] |volume=356 |issue=2 |pages=148–156 |year=2007 |month=January |pmid=17215532 |url=http://www.nejm.org/doi/pdf/10.1056/NEJMoa061189}}
* {{cite journal |author=Sternberg CN, Petrylak DP, Sartor O, ''et al.'' |title=Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial |journal=Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology |volume=27 |issue=32 |pages=5431–5438 |year=2009 |month=November |pmid=19805692 |doi=10.1200/JCO.2008.20.1228}}
* {{cite journal |author=Ricart AD, Sarantopoulos J, Calvo E, ''et al.'' |title=Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study |journal=Clinical Cancer Research : an Official Journal of the American Association for Cancer Research |volume=15 |issue=11 |pages=3866–3871 |year=2009 |month=June |pmid=19458055 |url=http://clincancerres.aacrjournals.org/content/15/11/3866.full.pdf}}
* {{cite journal |author=Kelland LR, Abel G, McKeage MJ, ''et al.'' |title=Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug |journal=Cancer Research |volume=53 |issue=11 |pages=2581–2586 |year=1993 |month=June |pmid=8388318 |url=http://cancerres.aacrjournals.org/content/53/11/2581.full.pdf}}
{{cite journal |author=Choy H, Park C, Yao M |title=Current status and future prospects for satraplatin, an oral platinum analogue |journal=Clinical Cancer Research : an Official Journal of the American Association for Cancer Research |volume=14 |issue=6 |pages=1633–1638 |year=2008 |month=March |pmid=18347164 |url=http://clincancerres.aacrjournals.org/content/14/6/1633.full.pdf}}
* {{Literatur
|Autor=Claus-Jürgen Estler
|Hrsg=Harald Schmidt
|Titel=Pharmakologie und Toxikologie für Studium und Praxis
|Auflage=6.
|Verlag=Schattauer GmbH
|Ort=Stuttgart
|Datum=2006
|ISBN=978-3-7945-2295-8
|Seiten=241–245}}
<ref>{{cite journal |author=Källén B, Mottet I |title=Delivery outcome after the use of meclozine in early pregnancy |journal=European Journal of Epidemiology |volume=18 |issue=7 |pages=665–669 |year=2003 |pmid=12952140 |url=http://www.kluweronline.com/art.pdf?issn=0393-2990&volume=18&page=665 |accessdate=2010-09-17}}</ref>
*{{cite journal |author=Lane AA, Chabner BA |title=Histone deacetylase inhibitors in cancer therapy |journal=Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology |volume=27 |issue=32 |pages=5459–5468 |year=2009 |month=November |pmid=19826124 |doi=10.1200/JCO.2009.22.1291 }}
*{{cite journal |author=Bonfils C, Kalita A, Dubay M, ''et al.'' |title=Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay |journal=Clinical Cancer Research : an Official Journal of the American Association for Cancer Research |volume=14 |issue=11 |pages=3441–3449 |year=2008 |month=June |pmid=18519775 |url=http://clincancerres.aacrjournals.org/content/14/11/3441.full.pdf }}
<ref name="pmid9834048">{{cite journal |author=Greenblatt DJ, Harmatz JS, von Moltke LL, ''et al.'' |title=Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo |journal=Clinical Pharmacology and Therapeutics |volume=64 |issue=5 |pages=553–561 |year=1998 |month=November |pmid=9834048 |doi=10.1016/S0009-9236(98)90139-4 |url= |issn= |accessdate=2010-09-06}}</ref>
<ref>{{cite journal |author=E. P. TCHERNOZATONSKAIA |title=THE USE OF PREGNANCY URINE AND PROLAN IN ANIMAL INDUSTRY |journal=Endocrinology |volume='''18''' |issue=4 |pages=482–486 |year=1934 |doi=10.1210/endo-18-4-482 |accessdate=2010-09-01 }}</ref>
{{cite journal |author=Bannen RM, Suresh V, Phillips GN Jr, Wright SJ, Mitchell JC |title=Optimal design of thermally stable proteins |journal=Bioinformatics |volume=24 |issue=20 |pages=2339–43 |year=2008 |pmid=18723523 |pmc=2562006 |doi=10.1093/bioinformatics/btn450 |url=http://bioinformatics.oxfordjournals.org/cgi/content/full/24/20/2339 }}
{{cite journal |journal= Energy Policy |year=2008 |volume=36 |issue=6 |pages=1858–1866 |title= Effect of daylight saving time on lighting energy use: a literature review |author= Myriam B.C. Aries; Guy R. Newsham |doi=10.1016/j.enpol.2007.05.021 |url=http://www.nrc-cnrc.gc.ca/obj/irc/doc/pubs/nrcc49212/nrcc49212.pdf |format=PDF |accessdate=2009-09-01 }}
<ref>{{cite journal |author=W. Philip T. James, M.D., D.Sc.,''et al.'' |title=Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects |journal=[[The New England Journal of Medicine]] |volume='''363''' |issue=10 |pages=905–917 |year=2010 |month=September |doi=10.1056/NEJMoa1003114 |accessdate=2010-09-02}}</ref>
http://www.nejm.org/doi/pdf/10.1056/NEJMoa1003114
905-917
<ref>{{cite journal |author=Krützfeldt J, Rajewsky N, Braich R, ''et al.'' |title=Silencing of microRNAs in vivo with 'antagomirs' |journal=[[Nature]] |volume='''438''' |issue=7068 |pages=685–689 |year=2005 |month=December |pmid=16258535 |doi=10.1038/nature04303 |accessdate=2010-08-31}}</ref>
<ref name="ema">{{cite web |url=http://www.ema.europa.eu/docs/de_DE/document_library/EPAR_-_Summary_for_the_public/human/000996/WC500019993.pdf |title=Zusammenfassung des Europäischen Öffentlichen Beurteilungsberichts (EPAR) für Cayston |format=PDF |publisher=veröffentlicht von der [[Europäische Arzneimittelagentur|Europäischen Arzneimittelagentur]] |pages=3 |language=de |accessdate= 2010-08-30}}</ref>
<references />
{{cite web | url= | title= | accessdate= | last= | first= | authorlink= | coauthors= | date=
| format= | work= | publisher= | pages= | language= | archiveurl= | archivedate= | quote= }}
<ref>{{cite journal |author=Brindani F, Vitetta F, Gemignani F |title=Restless legs syndrome: differential diagnosis and management with pramipexole |journal=Clinical Interventions in Aging |volume=4 |pages=305–313 |year=2009 |pmid=19750232 |pmc=2739631 |accessdate=2010-08-29}}</ref>
<ref>{{cite journal |author=Ferini-Strambi L, Aarskog D, Partinen M, ''et al.'' |title=Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial |journal=Sleep Medicine |volume=9 |issue=8 |pages=874–881 |year=2008 |month=December |pmid=18952497 |doi=10.1016/j.sleep.2008.09.001 |accessdate=2010-08-29}}</ref>
<ref name="pmid15262734">{{cite journal |author=Holloway RG, Shoulson I, Fahn S, ''et al.'' |title=Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial |journal=Archives of Neurology |volume=61 |issue=7 |pages=1044–1053 |year=2004 |month=July |pmid=15262734 |url=http://archneur.ama-assn.org/cgi/content/full/61/7/1044 |accessdate=2010-08-29}}</ref>
<ref>{{cite journal |author=Willett CG, Boucher Y, di Tomaso E, ''et al.'' |title=Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer |journal=Nature Medicine |volume=10 |issue=2 |pages=145–147 |year=2004 |month=February |pmid=14745444 |pmc=2693485 |accessdate=2010-08-28}}</ref>
<ref>{{cite journal |author=Mancuso MR, Davis R, Norberg SM, ''et al.'' |title=Rapid vascular regrowth in tumors after reversal of VEGF inhibition |journal=The Journal of Clinical Investigation |volume=116 |issue=10 |pages=2610–2621 |year=2006 |month=October |pmid=17016557 |pmc=1578604 |accessdate=2010-08-28}}</ref>
<ref>{{cite journal |author=Jain RK |title=Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy |journal=Science (New York, N.Y.) |volume=307 |issue=5706 |pages=58–62 |year=2005 |month=January |pmid=15637262 |doi=10.1126/science.1104819 |accessdate=2010-08-28}}</ref>
<ref name="pmid20719377">{{cite journal| author=Burns CM, Wortmann RL| title=Gout therapeutics: new drugs for an old disease. | journal=[[The Lancet]] | year= 2010 | volume= | issue= | pages= | pmid=20719377 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20719377 | doi=10.1016/S0140-6736(10)60665-4 }}</ref>
<ref name="pmid2071937">{{cite journal |author=Burns CM, Wortmann RL |title=Gout therapeutics: new drugs for an old disease |journal=[[The Lancet]] |volume= |issue= |pages= |year=2010 |month=August |pmid=20719377 |doi=10.1016/S0140-6736(10)60665-4 |url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(10)60665-4 |issn= |accessdate=2010-08-27}}</ref>
Innere Medizin kk: Febuxostat
{{Wikibooks|Innere Medizin kk: Febuxostat|Innere Medizin kk: Febuxostat|Febuxostat ist ein neues Medikament gegen die Gicht}}
{{Wikibooks|Pharmakologie und Toxikologie: Pharmakokinetik|Pharmakologie und Toxikologie: Pharmakokinetik}}
Pharmakologie und Toxikologie: Pharmakokinetik
[[Datei:Purin.svg|101px|Chemical structure of cytosine]]
[[Datei:Allopurinol V.1.svg|127px|Chemical structure of thymine]]
[[Datei:Febuxostat Structural Formulae V.1.svg|150px|Chemical structure of uracil]]
<ref name="pmid19671655">{{cite journal |author=Cummings SR, San Martin J, McClung MR, ''et al.'' |title=Denosumab for prevention of fractures in postmenopausal women with osteoporosis |journal=[[The New England Journal of Medicine]] |volume=361 |issue=8 |pages=756–765 |year=2009 |month=August |pmid=19671655 |url=http://www.nejm.org/doi/full/10.1056/NEJMoa0809493#articleTop |accessdate=2010-08-19}}</ref>
<ref name="pmid19671656">{{cite journal |author=Smith MR, Egerdie B, Hernández Toriz N, ''et al.'' |title=Denosumab in men receiving androgen-deprivation therapy for prostate cancer |journal=[[The New England Journal of Medicine]] |volume=361 |issue=8 |pages=745–755 |year=2009 |month=August |pmid=19671656 |url=http://www.nejm.org/doi/full/10.1056/NEJMoa0809003 |accessdate=2010-08-19}}</ref>
<ref name="pmid18381571">{{cite journal |author=Bone HG, Bolognese MA, Yuen CK, ''et al.'' |title=Effects of denosumab on bone mineral density and bone turnover in postmenopausal women |journal=The Journal of Clinical Endocrinology and Metabolism |volume=93 |issue=6 |pages=2149–2157 |year=2008 |month=June |pmid=18381571 |url=http://jcem.endojournals.org/cgi/content/full/93/6/2149 |accessdate=2010-08-19}}</ref>
{{RobKochInst|http://www.rki.de/cln_160/nn_205760/DE/Home/NDM-1.html?__nnn=true|Zum Auftreten von multiresistenten Erregern mit der Carbapenemase NDM-1}}
{{cite journal |author=Neumiller JJ |title=Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors |journal=Journal of the American Pharmacists Association : JAPhA |volume=49 Suppl 1 |issue= |pages=S16–29 |year=2009 |pmid=19801361 |url=http://japha.metapress.com/media/fl9xa52k5p6txj586ar6/contributions/8/3/5/4/8354267447045003_html/fulltext.html |accessdate=2010-08-17}}
{{cite journal |author=Svec F |title=Incretin physiology and its role in type 2 diabetes mellitus |journal=The Journal of the American Osteopathic Association |volume=110 |issue=7 Suppl 7 |pages=eS20–24 |year=2010 |month=July |pmid=20644202 |doi= |url=http://www.jaoa.org/cgi/pmidlookup?view=long&pmid=20644202 |accessdate=2010-08-17}}
{{cite journal |author=Grossman S |title=Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide |journal=Pharmacotherapy |volume=29 |issue=12 Pt 2 |pages=25S–32S |year=2009 |month=December |pmid=19947814 |url=http://www.atypon-link.com/PPI/doi/pdfplus/10.1592/phco.29.pt2.25S |accessdate=2010-08-17}}
{{cite journal |author=Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T |title=An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition |journal=The Journal of Biological Chemistry |volume=278 |issue=3 |pages=1848–1855 |year=2003 |month=January |pmid=12421831 |url=http://www.jbc.org/content/278/3/1848.full.pdf+html |accessdate=2010-08-16}}
{{cite journal |author=Schumacher HR, Becker MA, Lloyd E, MacDonald PA, Lademacher C |title=Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study |journal=Rheumatology (Oxford, England) |volume=48 |issue=2 |pages=188–194 |year=2009 |month=February |pmid=19141576 |url=http://rheumatology.oxfordjournals.org/cgi/content/full/48/2/188?view=long&pmid=19141576 |accessdate=2010-08-16}}
<ref name="pmid16166134">{{cite journal |author=Gutiérrez-Macías A, Lizarralde-Palacios E, Martínez-Odriozola P, Miguel-De la Villa F |title=Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia |journal=BMJ (Clinical Research Ed.) |volume=331 |issue=7517 |pages=623–624 |year=2005 |month=September |pmid=16166134 |pmc=1215560 |accessdate=2010-08-16}}</ref>
<ref name="pmid3947418">{{cite journal |author=Singer JZ, Wallace SL |title=The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality |journal=Arthritis and Rheumatism |volume=29 |issue=1 |pages=82–87 |year=1986 |month=January |pmid=3947418 |accessdate=2010-08-16}}</ref>
<ref name="pmid20142325">{{cite journal |author=Kelly CM, Juurlink DN, Gomes T, ''et al.'' |title=Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study |journal=BMJ (Clinical Research Ed.) |volume=340 |issue= |pages=c693 |year=2010 |pmid=20142325 |pmc=2817754 |accessdate=2010-08-14}}</ref>
<ref name="pmid19337428">{{cite journal |author=Hu M, Tomlinson B |title=Febuxostat in the management of hyperuricemia and chronic gout: a review |journal=Therapeutics and Clinical Risk Management |volume=4 |issue=6 |pages=1209–1220 |year=2008 |month=December |pmid=19337428 |pmc=2643102 |accessdate=2010-08-14}}</ref>
[[Arzneibuch#Europäisches Arzneibuch (Pharmacopoea Europaea)|Pharmacopoea Europaea]]
Laut [[Monografie]]-Nr.6.1/0293 in der [[Arzneibuch#Europäisches Arzneibuch (Pharmacopoea Europaea)|Ph. Eur. 6. Ausgabe, 5. Nachtrag]]
{{cite journal |author=Becker MA, Schumacher HR, Wortmann RL, ''et al.'' |title=Febuxostat compared with allopurinol in patients with hyperuricemia and gout |journal=[[The New England Journal of Medicine]] |volume=353 |issue=23 |pages=2450–2461 |year=2005 |month=December |pmid=16339094 |doi=10.1056/NEJMoa050373 |accessdate=2010-08-14}}
{{cite book |author=Otto Benkert, [[Hanns Hippius]], ''et al.'' |authorlink= |editor= |others= |title=Kompendium der Psychiatrischen Pharmakotherapie |edition=7. Auflage |language= |publisher=Springer |location=Berlin |year=2008 |origyear= |pages=308–311 |quote= |isbn=978-3-540-78470-8 |accessdate=2010-08-12}}
[[doi:10.1172/JCI38430]]
*{{cite journal |author=Liu M, Dilger JP |title=Site selectivity of competitive antagonists for the mouse adult muscle nicotinic acetylcholine receptor |journal=Molecular Pharmacology |volume=75 |issue=1 |pages=166–173 |year=2009 |month=January |pmid=18842832 |pmc=2606922 |accessdate=2010-08-05}}
*{{cite journal |author=Demazumder D, Dilger JP |title=The kinetics of competitive antagonism of nicotinic acetylcholine receptors at physiological temperature |journal=The Journal of Physiology |volume=586 |issue=4 |pages=951–963 |year=2008 |month=February |pmid=18063662 |pmc=2375649 |accessdate=2010-08-05}}
*{{cite journal |author=Dilger JP, Vidal AM, Liu M, ''et al.'' |title=Roles of amino acids and subunits in determining the inhibition of nicotinic acetylcholine receptors by competitive antagonists |journal=Anesthesiology |volume=106 |issue=6 |pages=1186–1195 |year=2007 |month=June |pmid=17525594 |pmc=2367005 |accessdate=2010-08-05}}
*{{cite journal |author=Kopman AF, Zank LM, Ng J, Neuman GG |title=Antagonism of cisatracurium and rocuronium block at a tactile train-of-four count of 2: should quantitative assessment of neuromuscular function be mandatory? |journal=Anesthesia and Analgesia |volume=98 |issue=1 |pages=102–106, table of contents |year=2004 |month=January |pmid=14693596 |url=http://www.anesthesia-analgesia.org/cgi/pmidlookup?view=long&pmid=14693596 |accessdate=2010-08-05}}
<ref name="pmid19455275">{{cite journal |author=Kasper S, Möller HJ, Hale A |title=The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment |journal=European Archives of Psychiatry and Clinical Neuroscience |volume=260 |issue=1 |pages=59–68 |year=2010 |month=February |pmid=19455275 |url=http://www.springerlink.com/content/ap535352047u7408/fulltext.pdf |accessdate=2010-08-10}}</ref>
<ref name="pmid18638382">{{cite journal |author=Lançon C, Toumi M, Sapin C, Hansen K |title=The Sertindole Safety Survey: a retrospective analysis under a named patient use programme in Europe |journal=BMC Psychiatry |volume=8 |issue= |pages=57 |year=2008 |pmid=18638382 |pmc=2496904 |accessdate=2010-08-10}}</ref>
<ref name="pmid2753814">{{cite journal |author=Lee MD, Manning JK, Williams DR, Kuck NA, Testa RT, Borders DB |title=Calicheamicins, a novel family of antitumor antibiotics. 3. Isolation, purification and characterization of calicheamicins beta 1Br, gamma 1Br, alpha 2I, alpha 3I, beta 1I, gamma 1I and delta 1I |journal=The Journal of Antibiotics |volume=42 |issue=7 |pages=1070–1087 |year=1989 |month=July |pmid=2753814 |accessdate=2010-08-08}}</ref>
<ref>{{Cite web |url=http://www.telegraph.co.uk/news/worldnews/europe/greece/7924855/Alexander-the-Great-poisoned-by-the-River-Styx.html |title=Alexander the Great poisoned by the River Styx |date=2010-08-04|accessdate=2010-08-08}}</ref>
<ref name="pmid19028103">{{cite journal |author=Nicolaou KC, Chen JS, Dalby SM |title=From nature to the laboratory and into the clinic |journal=Bioorganic & Medicinal Chemistry |volume=17 |issue=6 |pages=2290–2303 |year=2009 |month=March |pmid=19028103 |pmc=2665039 |accessdate=2010-08-07}}</ref>
<ref name="pmid11255078">{{cite journal |author=Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG |title=Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy |journal=Critical Reviews in Oncology/hematology |volume=38 |issue=1 |pages=17–23 |year=2001 |month=April |pmid=11255078 |url=http://www.croh-online.com/article/PIIS1040842800001347/fulltext |accessdate=2010-08-04}}</ref>
<ref name="pmid18316791">{{cite journal |author=Amado RG, Wolf M, Peeters M, ''et al.'' |title=Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer |journal=Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology |volume=26 |issue=10 |pages=1626–1634 |year=2008 |month=April |pmid=18316791 |url=http://jco.ascopubs.org/cgi/content/full/26/10/1626 |accessdate=2010-08-04}}</ref>
<ref name="pmid18703474">{{cite journal |author=Anton RF |title=Naltrexone for the management of alcohol dependence |journal=[[The New England Journal of Medicine]] |volume=359 |issue=7 |pages=715–721 |year=2008 |month=August |pmid=18703474 |pmc=2565602 |accessdate=2010-08-01}}</ref>
<ref name="pmid16433053">{{cite journal |author=López-Muñoz F, Alamo C, Cuenca E, Shen WW, Clervoy P, Rubio G |title=History of the discovery and clinical introduction of chlorpromazine |journal=Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists |volume=17 |issue=3 |pages=113–135 |year=2005 |pmid=16433053 |accessdate=2010-07-31}}</ref>
<ref name="pmid16557334">{{cite journal |author=Leoni F, Fossati G, Lewis EC, ''et al.'' |title=The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo |journal=Molecular Medicine (Cambridge, Mass.) |volume=11 |issue=1–12 |pages=1–15 |year=2005 |pmid=16557334 |pmc=1449516 |accessdate=2010-07-24}}</ref>
{{cite journal |author=Gregoire FM, Zhang F, Clarke HJ, ''et al.'' |title=MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema |journal=Molecular Endocrinology (Baltimore, Md.) |volume=23 |issue=7 |pages=975–988 |year=2009 |month=July |pmid=19389808 |doi=10.1210/me.2008-0473 |url= |issn= |accessdate=2010-07-21}}
<ref>{{cite journal |journal=Journal für Gastroenterologische und Hepatologische Erkrankungen |year=2010 |volume= |issue=8 |pages=1–7 |title=Schaumzerstörung und Schaumverhinderung: Der Wirkmechanismus von Simeticon in vitro |author=M. Dittrich, S. E. Miederer, B. Havertz, R. Krastev |url=http://www.kup.at/kup/pdf/8860.pdf |format=PDF |accessdate=2010-07-26}}</ref>
{{cite journal |author=André G. Aeschlimann, Felix Angst, Daniel Eschle, Andreas Thueler |title=Nackenschmerzen |journal=Schweizerisches Medizin-Forum |volume=10 |issue=11 |pages=208–213 |year=2010 |url=http://www.medicalforum.ch/pdf/pdf_d/2010/2010-11/2010-11-110.PDF |accessdate=2010-07-25}}
{{cite journal |author=Rackoff P |title=Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis |journal=Clinical Interventions in Aging |volume=4 |issue= |pages=207–214 |year=2009 |pmid=19503783 |pmc=2685242 |accessdate=2010-07-10}}
<ref name="pmid11117978">{{cite journal |author=Meininger ME, Kendler JS |title=Images in clinical medicine. Trousseau's sign |journal=[[The New England Journal of Medicine]] |volume=343 |issue=25 |pages=1855 |year=2000 |month=December |pmid=11117978 |doi= |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=11117978&promo=ONFLNS19 |issn= |accessdate=2010-07-16}}</ref>
<ref name="pmid">{{cite journal |author=Meininger ME, Kendler JS |title=Images in clinical medicine. Trousseau's sign |journal=[[The New England Journal of Medicine]] |volume=343 |issue=25 |pages=1855 |year=2000 |month=December |pmid=11117978 | url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=11117978&promo=ONFLNS19 |accessdate=2010-07-16}}</ref>
<ref name="pmid19942469">{{cite journal |author=Watts NB, Brown JP, Cline G |title=Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1year compared with historical placebo |journal=Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry |volume=13 |issue=1 |pages=56–62 |year=2010 |pmid=19942469 | url=http://linkinghub.elsevier.com/retrieve/pii/S1094-6950(09)00234-0 |accessdate=2010-07-11}}</ref>
<ref name="pmid15187244">{{cite journal |author=Langston AL, Ralston SH |title=Management of Paget's disease of bone |journal=Rheumatology (Oxford, England) |volume=43 |issue=8 |pages=955–959 |year=2004 |month=August |pmid=15187244 | |url=http://rheumatology.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=15187244 |accessdate=2010-07-11}}</ref>
<ref>[http://www.embryotox.de/carbamazepin.html ''Embriotox-Arzneimittelsicherheit in Schwangerschaft und Stillzeit: Daten für Carbamazepin''] abgerufen am 10 Juli 2010.</ref>
<ref name="pmid19966913">{{cite journal |author=Masud T, McClung M, Geusens P |title=Reducing hip fracture risk with risedronate in elderly women with established osteoporosis |journal=Clinical Interventions in Aging |volume=4 |pages=445–449 |year=2009 |pmid=19966913 |pmc=2785868 |accessdate=2010-07-10}}</ref>
* [http://toolserver.org/~escaladix/cgi-bin/farticles.tcl?pseudo=Crazy-Chemist&lang=de Artikelstatiskit]
* [http://sumsearch.uthscsa.edu/cite/ Wiki and Blog citation maker]
{{RobKochInst|http://www.rki.de/cln_179/nn_196658/DE/Content/InfAZ/L/Lebensmittel/Lebensmittel.html|Lebensmittelbedingte Erkrankungen}}
{{AWMF|http://www.uni-duesseldorf.de/WWW/AWMF/ll/030-081.htm|Restless-Legs-Syndrom (RLS) und Periodic Limb Movement Disorder (PLMD)|S1|Deutschen Gesellschaft für Neurologie|Oktober 2008}}
[[Cochrane Library]]
* {{cite journal |author=Fromtling RA |title=Overview of medically important antifungal azole derivatives |journal=Clinical Microbiology Reviews |volume=1 |issue=2 |pages=187–217 |year=1988 |month=April |pmid=3069196 |pmc=358042 |accessdate=2010-06-27}}
[[WP:RMLL#A3]]
<ref name="pmid11810493">{{cite journal |author=Nakajima Y |title=Mechanisms of bacterial resistance to macrolide antibiotics |journal=Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy |volume=5 |issue=2 |pages=61–74 |year=1999 |month=June |pmid=11810493 |url=http://www.springerlink.com/content/830ayeckra7xkudf/fulltext.pdf |issn= |accessdate=2010-07-01}}</ref>
<ref name="pmid1181049">{{cite journal |author=Nakajima Y |title=Mechanisms of bacterial resistance to macrolide antibiotics |journal=Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy |volume=5 |issue=2 |pages=61–74 |year=1999 |month=June |pmid=11810493 |doi=10.1007/s101569900000 |url=http://link.springer.de/link/service/journals/10156/bibs/9005002/90050061.htm |issn= |accessdate=2010-07-01}}</ref>
<ref name="pmid7687646">{{cite journal |author=Pernodet JL, Alegre MT, Blondelet-Rouault MH, Guérineau M |title=Resistance to spiramycin in Streptomyces ambofaciens, the producer organism, involves at least two different mechanisms |journal=Journal of General Microbiology |volume=139 |issue=5 |pages=1003–1011 |year=1993 |month=May |pmid=7687646 | |url=http://mic.sgmjournals.org/cgi/reprint/139/5/1003.pdf |accessdate=2010-07-01}}</ref>
<ref name="pmid583241">{{cite journal |author=Kessler HJ |title=[Microbiological studies on isoconazole nitrate, a broad spectrum antimycotic from the series of imidazole derivatives (author's transl)] |language=German |journal=Arzneimittel-Forschung |volume=29 |issue=9 |pages=1344–1351 |year=1979 |pmid=583241 |doi= |url= |issn= |accessdate=2010-06-27}}</ref>
<ref name="pmid19370679">{{cite journal |author=Minozzi S, Amato L, Davoli M |title=Maintenance treatments for opiate dependent adolescent |journal=Cochrane Database of Systematic Reviews |issue=2 |year=2009 |pmid=19370679 |url=http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD007210/pdf_abstract_fs.html |accessdate=2010-06-26}}</ref>
{{AWMF|http://www.uni-duesseldorf.de/AWMF/ll/065-003.htm|Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (PAVK)|S3|Deutschen Gesellschaft für Angiologie - Gesellschaft für Gefäßmedizin|03/2009}}
{{AWMF|http://www.uni-duesseldorf.de/AWMF/ll/053-007.pdf|Nackenschmerzen|S3|Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM)|Juni 2009}}
{{AWMF|http://www.uni-duesseldorf.de/AWMF/ll/005-003.htm|Diagnostik und Therapie des Karpaltunnelsyndroms|S3|Deutschen Gesellschaft für Orthopädie und Orthopädische Chirurgie|November 2006}}
{{cite journal | author = Zangara A | title = The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease | journal = Pharmacology, Biochemistry, and Behavior | volume = 75 | issue = 3 | pages = 675–686 | year = 2003 | month = June | pmid = 12895686 | doi = | url = http://linkinghub.elsevier.com/retrieve/pii/S0091305703001114 | issn = | accessdate = 2010-05-25}}
{{cite journal |author=Zangara A |title=The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease |journal=Pharmacology, Biochemistry, and Behavior |volume=75 |issue=3 |pages=675–686 |year=2003 |month=June |pmid=12895686 |url=http://linkinghub.elsevier.com/retrieve/pii/S0091305703001114 |accessdate=2010-05-25}}
* [http://www.zct-berlin.de/neueinfuehrungen/cefpodoxim.html Cefpodoxim-Proxetil - ein neues Cephalosporin zur oralen Anwendung] in der Zeitschrift für Chemotherapie, Heft 1, Berlin 1992
{{Literatur |Hrsg=J.C. Frölich, W. Kirch |Titel=Praktische Arzneitherapie |Verlag=Springer-Verlag GmbH |Datum=2003 |ISBN=978-3-540-01025-8 |Seiten=543–545 |Online={{Google Buch|BuchID=orOO8FqNzDcC&pg=PA543|Linktext=Auszug}}}}
{{Literatur |Autor=Ulrike Hellert |Titel=Praxis der Nacht- und Schichtplangestaltung: Mit Ernährungsempfehlungen von Wolfgang Sichert-Hellert |Verlag=Lit Verlag |Datum=2008 |ISBN=978-3-8258-0997-3 |Online=
{{Google Buch
| BuchID = Mg1Zwp1MMYkC&pg=PA17
| Linktext = Volltext
}}}}
http://flexikon.doccheck.com/Idiopathische_thrombozytopenische_Purpura?q=idiopathische+thrombozytopenische+purpura+
{| {{Bausteindesign2}}
| Dieser Text basiert ganz oder teilweise auf dem [http://flexikon.doccheck.com/{{#if:Idiopathische_thrombozytopenische_Purpura|/Idiopathische_thrombozytopenische_Purpura|}} Flexikon], einem Wiki der Firma [[DocCheck]] und ist unter [[GNU-Lizenz für freie Dokumentation|GNU-FDL]] lizenziert.
|}
{{Flexikon|Artikelname bei Flexikon}}
siehe [[WP:RMLL#A3]]
siehe [[WP:RMLL#D]]
siehe [[WP:RMEL]]
{{Google Buch |BuchID=6G0I35aJ3zcC&pg=PA168&dq=spiramycin&hl#v=onepage&q=spiramycin&f=false |Linktext=Auszug}}
<ref name=" ISBN 1-58829-009-3">{{Literatur |Autor=Vassol St Georgiev |Titel=Opportunistic Infections (Infectious Disease (Totowa, N.J.).) |Verlag=Humana Press |Datum=2001 |ISBN=1-58829-009-3 |Online={{Google Buch |BuchID=6G0I35aJ3zcC&pg=PA168&dq=spiramycin&hl#v=onepage&q=spiramycin&f=false |Linktext=Auszug}}}}</ref>
{{cite book |author=Frank J. Hennecke; Eisenbrand, Gerhard; Metzler, Manfred |authorlink= |editor= |others= |title=Toxikologie Fur Naturwissenschaftler Und Mediziner: Stoffe, Mechanismen, Prufverfahren (German Edition) |edition=3 |language= |publisher=Wiley-VCH Verlag GmbH |location=Weinheim |year=2005 |origyear= |pages=378 |quote= |isbn=978-3-527-30989-4 |accessdate=}}
<ref name="pmid3833809">{{cite journal| author=Hunt DE, Lipton DS, Goldsmith DS, Strug DL, Spunt B| title="It takes your heart": the image of methadone maintenance in the addict world and its effect on recruitment into treatment. | journal=Int J Addict | year= 1985 Nov-Dec | volume= 20 | issue= 11-12 | pages= 1751-1771 | pmid=3833809
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=3833809}}</ref>
<ref name="pmid383389">{{cite journal |author=Hunt DE, Lipton DS, Goldsmith DS, Strug DL, Spunt B |title="It takes your heart": the image of methadone maintenance in the addict world and its effect on recruitment into treatment |journal=The International Journal of the Addictions |volume=20 |issue=11-12 |pages=1751–1771 |year=1985 |pmid=3833809 |doi=10.3109/10826088509047261 |accessdate=2010-06-24}}</ref>
<ref name="pmid9068192">{{cite journal |author=Hochmeister MN, Whelan M, Borer UV, ''et al.'' |title=Effects of toluidine blue and destaining reagents used in sexual assault examinations on the ability to obtain DNA profiles from postcoital vaginal swabs |journal=Journal of Forensic Sciences |volume=42 |issue=2 |pages=316–319 |year=1997 |month=March |pmid=9068192 |accessdate=2010-06-21}}</ref>
<ref name="pmid19242663">{{cite journal |author=Gillissen A, ''et al.'' |title=Klinische Bedeutung der forcierten Einsekundenkapazität (FEV1) bei chronisch-obstruktiver Lungenerkrankung (COPD) |journal=Medizinische Klinik |volume=104 |issue=2 |pages=119–124 |year=2009 |month=Februar |pmid=19242663 |doi=10.1007/s00063-009-1023-9 |url=http://www.springerlink.com/content/677042878w2j407m/fulltext.pdf |accessdate=2010-06-21}}</ref>
<ref name="pmid20109995">{{cite journal |author=Schilit S, Benzeroual KE |title=Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia |journal=Clinical Therapeutics |volume=31 |issue=11 |pages=2489–2502 |year=2009 |month=November |pmid=20109995 |doi=10.1016/j.clinthera.2009.11.024 |accessdate=2010-06-20}}</ref>
<ref name="pmid19536124">{{cite journal |author=Kobayashi K, Masumori N, Kato R, Hisasue S, Furuya R, Tsukamoto T |title=Orgasm is preserved regardless of ejaculatory dysfunction with selective alpha1A-blocker administration |journal=International Journal of Impotence Research |volume=21 |issue=5 |pages=306–310 |year=2009 |pmid=19536124 |pmc=2834370 |accessdate=2010-06-20}}</ref>
<ref name="pmid18223667">{{cite journal |author=Morishima S, Suzuki F, Yoshiki H, ''et al.'' |title=Identification of the alpha1L-adrenoceptor in rat cerebral cortex and possible relationship between alpha1L- and alpha1A-adrenoceptors |journal=British Journal of Pharmacology |volume=153 |issue=7 |pages=1485–1494 |year=2008 |month=April |pmid=18223667 |pmc=2437907 |accessdate=2010-06-20}}</ref>
<ref name="pmid12071539">{{cite journal |author=Carley DW, Paviovic S, Janelidze M, Radulovacki M |title=Functional role for cannabinoids in respiratory stability during sleep |journal=Sleep |volume=25 |issue=4 |pages=391–398 |year=2002 |month=June |pmid=12071539 |accessdate=2010-06-19}}</ref>
<ref name="pmid13409110">{{cite journal |author=ROBINSON MM |title=Use of dimethisoquin in pruritic dermatoses: a three year study |journal=Southern Medical Journal |volume=50 |issue=3 |pages=367–9 |year=1957 |month=March |pmid=13409110 | |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0038-4348&volume=50&issue=3&spage=367 |accessdate=2010-06-17}}</ref>
{{cite book |author=Ashutosh Kar |authorlink= |editor= |others= |title=Medicinal Chemistry |edition=3 |language=en |publisher=Anshan Ltd |location= |year=2006 |origyear= |pages=804 |quote= |isbn=978-1-904798-76-7
|oclc= |doi= |url= |accessdate=}}
<ref name="pmid11714893">{{cite journal |author=Gentry CL, Lukas RJ |title=Local anesthetics noncompetitively inhibit function of four distinct nicotinic acetylcholine receptor subtypes |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=299 |issue=3 |pages=1038–1048 |year=2001 |month=December |pmid=11714893 |doi= |url=http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=11714893 |issn= |accessdate=2010-06-17}}</ref>
<ref name="pmid18547127">{{cite journal |author=Nakagawa A, Watanabe N, Omori IM, ''et al.'' |title=Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants : a systematic review and meta-analysis |journal=CNS Drugs |volume=22 |issue=7 |pages=587–602 |year=2008 |pmid=18547127 |accessdate=2010-06-16}}</ref>
<ref name="pmid11694882">{{cite journal | author = Schittek B, Hipfel R, Sauer B, ''et al.'' | title = Dermcidin: a novel human antibiotic peptide secreted by sweat glands | journal = Nature Immunology | volume = 2 | issue = 12 | pages = 1133–1137 | year = 2001 | month = December | pmid = 11694882 | url = http://www.kalbacher.uni-tuebingen.de/pdf/2001/hk20013.pdf | accessdate = 2010-06-13}}</ref>
<ref name="pmid16117788">{{cite journal |author=De Vry CG, Valdez M, Lazarov M, ''et al.'' |title=Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model |journal=The Journal of Investigative Dermatology |volume=125 |issue=3 |pages=473–481 |year=2005 |month=September |pmid=16117788 |url=http://www.nature.com/jid/journal/v125/n3/pdf/5603514a.pdf |accessdate=2010-06-10}}</ref>
<ref name="pmid18162370">{{cite journal |author=Liu W, Deyoung BR, Chen X, Evanoff DP, Luo Y |title=RDP58 inhibits T cell-mediated bladder inflammation in an autoimmune cystitis model |journal=Journal of Autoimmunity |volume=30 |issue=4 |pages=257–265 |year=2008 |month=June |pmid=18162370 |pmc=2441447 |url=http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2441447/pdf/nihms-50573.pdf |issn= |accessdate=2010-06-10}}</ref>
<ref name="pmid1816237">{{cite journal | author = Liu W, Deyoung BR, Chen X, Evanoff DP, Luo Y | title = RDP58 inhibits T cell-mediated bladder inflammation in an autoimmune cystitis model | journal = Journal of Autoimmunity | volume = 30 | issue = 4 | pages = 257–265 | year = 2008 | month = June | pmid = 18162370 | pmc = 2441447 | url = | issn = | accessdate = 2010-06-10}}</ref>
http://books.google.com/books?id=KxTKLlac60wC&pg=PA55&dq=laudanosine&sig=ACfU3U2OZxmvO0Pl8Jnp8KuGXHzMllcnQA#v=onepage&q=laudanosine&f=false
<ref>{{cite book |chapterurl=http://books.google.com/books?id=KxTKLlac60wC&pg=PA55&dq=laudanosine&sig=ACfU3U2OZxmvO0Pl8Jnp8KuGXHzMllcnQA#PPA48,M1 |chapter=The Benzylisoquinoline Alkaloids |author=Burger A |title=The Alkaloids: Chemistry and Physiology |origyear=1954 |year=2005 |volume=4 |editor=Manske RHF, Holmes HL (eds.) |pages=p. 48 |location=New York |publisher=Academic Press |isbn=0-12-469504-3}} Retrieved September 18, 2008 through [[Google Book Search]].</ref>
{{cite journal| author=Bacchi CJ, Weiss LM, Lane S, Frydman B, Valasinas A, Reddy V et al.| title=Novel synthetic polyamines are effective in the treatment of experimental microsporidiosis, an opportunistic AIDS-associated infection. | journal=Antimicrob Agents Chemother | year= 2002 | volume= 46 | issue= 1 | pages= 55–61 | pmid=11751111
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=11751111 | pmc=PMC127003| accessdate = 2010-06-03}}
<ref name="pmid2650860">{{cite journal| author=Shadduck JA, Greeley E| title=Microsporidia and human infections. | journal=Clin Microbiol Rev | year= 1989 | volume= 2 | issue= 2 | pages= 158–165 | pmid=2650860
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=2650860 | pmc=PMC358108| accessdate = 2010-06-02}}</ref>
<ref name="pmid26500">{{cite journal| author=Shadduck JA, Greeley E| title=Microsporidia and human infections. | journal=Clin Microbiol Rev | year= 1989 | volume= 2 | issue= 2 | pages= 158-165 | pmid=2650860 | pmc=358108 | accessdate = 2010-06-02}}</ref>
<ref name="pmid18231614">{{cite journal | author = Lepor H | title = Alpha blockers for the treatment of benign prostatic hyperplasia | journal = Reviews in Urology | volume = 9 | issue = 4 | pages = 181–190 | year = 2007 | pmid = 18231614 | pmc = 2213889 | doi = | url = | issn = | accessdate = 2010-05-30}}</ref>
<ref name="pmid20126606">{{cite journal | author = Roehrborn CG | title = Efficacy of alpha-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms |journal = Reviews in Urology |volume = 11 |issue = Suppl 1 |pages = S1–8 | year = 2009 |pmid = 20126606 |pmc = 2812889 |accessdate = 2010-05-30}}</ref>
<ref name="pmid18855806">{{cite journal | author = Haney M | title = Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls | journal = Addiction Biology | volume = 14 | issue = 1 | pages = 9–21 | year = 2009 | month = January | pmid = 18855806 | pmc = 2743289 | doi = 10.1111/j.1369-1600.2008.00121.x | url = | issn = | accessdate = 2010-05-14}}</ref>
<ref name="pmid6124415">{{cite journal | author = Kanto JH | title = Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations | journal = Drugs | volume = 23 | issue = 5 | pages = 354–80 | year = 1982 | month = May | pmid = 6124415 | doi = | url = http://content.wkhealth.com/linkback/openurl?issn=0012-6667&volume=23&issue=5&spage=354 | issn = | accessdate = 2010-05-12}}</ref>
<ref name="pmid61244">{{cite journal | author = Kanto JH | title = Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations | journal = Drugs | volume = 23 | issue = 5 | pages = 354–80 | year = 1982 | month = May | pmid = 6124415 | doi = | url = | issn = | accessdate = 2010-05-12}}</ref>
<ref name="pmid6124">{{cite journal | author = Kanto JH | title = Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations | journal = Drugs | volume = 23 | issue = 5 | pages = 354–380 | year = 1982 | month = May | pmid = 6124415 | accessdate = 2010-05-12}}</ref>
<ref name="FI">Fachinformation aus dem [[Arzneimittel-Kompendium der Schweiz]] für
''Anafranil<sup>®</sup>'' von Novartis Pharma Schweiz – Stand: Mai 2009</ref>
<ref name=" ISBN 3-7691-0424-2">{{cite book | author = Knuth, Peter; Loch, Franz-Carl | authorlink = | editor = | others = | title = Notfälle nach Leitsymptomen | edition =5 | language = | publisher = Deutscher Aerzte-Verlag | location =Köln | year = 2006 | origyear = | pages =673 | quote = | isbn = 978-3-7691-0424-0 | oclc = | doi = | url = | accessdate = }}</ref>
"..." (drei Zeichen) statt "…".
{{cite book | author = Otto Benkert; Holsboer, Florian; Gerhard Gründer | title = Handbuch der Psychopharmakotherapie | edition = 1.| publisher = Springer | location = Berlin | year = 2007 | pages = 1185 | isbn = 978-3-540-20475-6| doi = 10.1007/978-3-540-68748-1}}
http://books.google.ch/books?id=IBJSDIxrSUUC&pg=PA696&dq=W.+Remmele++Pathologie++3.+Auflage,+Verlag+Springer+2008&hl=de&ei=RAnHS_mGCNOosQbb_cHfCg&sa=X&oi=book_result&ct=result&resnum=1&ved=0CDcQ6AEwAA#v=snippet&q=rundzellige%20Liposarkome%20&f=false
Ubidecarenon is the German [[Internationaler Freiname|INN]], it has also an {{ATC|Q|P53AX11}} and an entry in the European Pharmacopoeia. [http://crs.edqm.eu/db/4DCGI/db/4DCGI/MSDS?MSDS=U0020000 Safety Data Sheet for ''UBIDECARENONE CRS''] – [[Europäisches Direktorat für die Qualität von Arzneimitteln|EDQM]], abgerufen am 8. April 2010.
http://books.google.ch/books?id=Mg1Zwp1MMYkC&pg=PA17&dq=Biologische+Leistungskurve+des+Menschen&hl=de&ei=XN_FS47BIoinsAa0uOG-AQ&sa=X&oi=book_result&ct=result&resnum=1&ved=0CDUQ6AEwAA#v=onepage&q&f=false
http://books.google.ch/books?id=Mg1Zwp1MMYkC&pg=PA18&dq=Biologische+Leistungskurve+des+Menschen&as_brr=3&cd=1#v=onepage&q=Biologische%20Leistungskurve%20des%20Menschen&f=false
<ref name="pmid18072812">{{cite journal | author = Kasper S, McEwen BS | title = Neurobiological and clinical effects of the antidepressant tianeptine | journal = CNS Drugs | volume = 22 | issue = 1 | pages = 15–26 | year = 2008 | pmid = 18072812 | doi = | url = http://adisonline.com/cnsdrugs/Fulltext/2008/22010/Neurobiological_and_Clinical_Effects_of_the.2.aspx# | issn = | accessdate = 2010-05-09}}</ref>
<ref name="pmid11157560">{{cite journal | author = Manson AJ, Hanagasi H, Turner K, ''et al.'' | title = Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations | journal = Brain : a Journal of Neurology | volume = 124 | issue = Pt 2 | pages = 331–340 | year = 2001 | month = February | pmid = 11157560 | doi = | url = http://brain.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=11157560 | accessdate = 2010-04-30}}</ref>
<ref name="pmid20194335">{{cite journal | author = Unnanuntana A, Gladnick BP, Donnelly E, Lane JM | title = The assessment of fracture risk | journal = The Journal of Bone and Joint Surgery| volume = 92 | issue = 3 | pages = 743–753 | year = 2010 | month = March | pmid = 20194335 | url =http://www.ejbjs.org/cgi/content/full/92/3/743 | accessdate = 2010-04-29}}</ref>
<ref name="ema">{{cite web |url=http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000109/WC500056580.pdf |title=Scientific discussion for the approval of RILUTEK |date=2004-01-01 | format=PDF |publisher=[[Europäische Arzneimittelagentur]] |pages=12 |language=en |accessdate= 2010-08-10}}</ref>
<ref name="pmid11929256">{{cite journal | author = Isomura S, Hoffman TZ, Wirsching P, Janda KD | title = Synthesis, properties, and reactivity of cocaine benzoylthio ester possessing the cocaine absolute configuration | journal = Journal of the American Chemical Society | volume = 124 | issue = 14 | pages = 3661–3668 | year = 2002 | month = April | pmid = 11929256 | url = http://dx.doi.org/10.1021/ja012376y | accessdate = 2010-04-07}}</ref>
<ref name="pmid1192925">{{cite journal| author=Isomura S, Hoffman TZ, Wirsching P, Janda KD| title=Synthesis, properties, and reactivity of cocaine benzoylthio ester possessing the cocaine absolute configuration. | journal=J Am Chem Soc | year= 2002 | volume= 124 | issue= 14 | pages= 3661–3668 | pmid=11929256
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=11929256}}</ref>
<ref name="pmid15548587">{{cite journal| author=Usmani OS, Belvisi MG, Patel HJ, Crispino N, Birrell MA, Korbonits M et al.| title=Theobromine inhibits sensory nerve activation and cough. | journal=FASEB J | year= 2005 | volume= 19 | issue= 2 | pages= 231-3 | pmid=15548587
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=15548587 | doi=10.1096/fj.04-1990fje | quote= These data indicate the actions of theobromine appear to be peripherally mediated. We conclude theobromine is a novel and promising treatment, which may form the basis for a new class of antitussive drugs. }}</ref>
*{{Literatur
|Autor=P. Altmeyer
|Titel=Enzyklopädie der Dermatologie, Venerologie, Allergologie, Umweltmedizin
|Datum=2008
|ISBN=978-3-540-41361-5
|Kommentar=Eintrag ''Id-Reaktion''
|Online=[http://132.187.10.79/login/n/h/1921_1.htm Online]
|Abruf=2010-03-08}}
{{cite book |author=[[Louis Lewin]] |authorlink= |title=Phantastica - Die betäubenden und erregenden Genußmittel - Für Ärzte und Nichtärzte |edition= |language=de |publisher=Voltmedia GmbH |location= Paderborn |year=2005 |origyear= |pages=508 |quote= |isbn=978-3-937229-68-3 |url=[http://books.google.ch/books?id=5GPthV9MyccC&printsec=frontcover&dq=Lewin+Louis+Phantastica&as_brr=3&cd=1#v=onepage&q=&f=false Hier online (englisch)] |accessdate=}}
{{cite book | author = M. Stucker; Altmeyer, Peter; M. Bacharach-Buhles; N. Buhles; Brockmeyer, Neal H.; M. Herde | authorlink = | editor = | others = | title = Springer Enzyklopädie Dermatologie, Allergologie, Umweltmedizin | edition = | language = | publisher = Springer | location = Berlin | year = 2002 | origyear = | pages = | quote = | isbn = 3-540-41361-8 | oclc = | doi = | url = | accessdate = 2010-03-08 }}
{{cite journal | author = Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P | title = Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial | journal = Lancet | volume = 375 | issue = 9717 | pages = 807–815 | year = 2010 | month = March | pmid = 20206776 |url = | issn = | accessdate = 2010-03-25}}
<ref name="bfarm.de">{{cite web | url =http://www.bfarm.de/cln_028/nn_1095560/SharedDocs/Publikationen/DE/Pharmakovigilanz/roteHandBriefe/2010/reductil,templateId=raw,property=publicationFile.pdf/reductil.pdf | title =Ruhen der Marktzulassung für Reductil® (Wirkstoff Sibutramin) wegen der
Beobachtung eines erhöhten kardiovaskulären Risikos im Rahmen der SCOUT-Studie | author = | authorlink = | coauthors = | date = 2010-01-22| format = | accessdate = 2010-02-01}}</ref>
<ref>[http://www.bfarm.de/cln_028/nn_1095560/SharedDocs/Publikationen/DE/Pharmakovigilanz/roteHandBriefe/2010/reductil,templateId=raw,property=publicationFile.pdf/reductil.pdf Ruhen der Marktzulassung für Reductil wegen der Beobachtung eines erhöhten kardiovaskulären Risikos im Rahmen der SCOUT-Studie] Rote Hand Brief vom 22. Januar 2010</ref>
{{cite web |url=http://deposit.ddb.de/cgi-bin/dokserv?idn=970935765&dok_var=d1&dok_ext=pdf&filename=970935765.pdf |title=Genetische Defekte im renalen Cystintransport und ihre Bedeutung für die Cystinurie |author= Christa Schmidt|date=2004 |format=PDF |work= Dissertation der Fakultät für Biologie der Eberhard-Karls-Universität Tübingen|publisher= |pages= 133| accessdate=2010-01-16}}
{{cite journal | author = Duschek S, Muckenthaler M, Werner N, del Paso GA | title = Relationships between features of autonomic cardiovascular control and cognitive performance | journal = Biological Psychology | volume = 81 | issue = 2 | pages = 110–117 | year = 2009 | month = May | pmid = 19428975 | doi = 10.1016/j.biopsycho.2009.03.003 | url = | issn = | accessdate = 2010-01-27}}
<ref name="pmid19877246">{{cite journal | author = Soyka MB, Rufibach K, Huber A, Holzmann D | title = Is severe epistaxis associated with acetylsalicylic acid intake? | journal = The Laryngoscope | volume = 120 | issue = 1 | pages = 200–207 | year = 2010 | month = January | pmid = 19877246 | doi = 10.1002/lary.20695 | url = | issn = }}</ref>
<ref name="urlwww.goldenetablette.de">{{cite web | url = http://www.goldenetablette.de/fileadmin/uploads/Siegeruebersicht/Liste_GT_IP_2000_2009_Seite5.pdf | title = Alle Gewinner des Innovativsten Produkts 2000–2009 | format = pdf| work = | publisher = | pages = 1| language = | archiveurl = | archivedate = | quote = | accessdate = 2010-01-14}}</ref>
<ref name="CYSTINURIA">{{cite journal | url = http://www.jbc.org/content/86/1/315.full.pdf+html | author = Erwin Brand, Meyer M. Harris, and Sol Biloon | title = Cystinuria: The excretion of cystine complex which decomposes in the urine with the liberation of free cystine | journal = The Journal of biological chemistry| volume = 1 | issue = 86| pages = 315–331| year = 1930| month = march| accessdate = 2010-01-16}}</ref>
<ref name="pmid18771264">{{cite journal | author = Nicolaou KC, Stepan AF, Lister T, ''et al.'' | title = Design, synthesis, and biological evaluation of platensimycin analogues with varying degrees of molecular complexity | journal = Journal of the American Chemical Society | volume = 130 | issue = 39 | pages = 13110–13119 | year = 2008 | month = October | pmid = 18771264 | pmc = 2669665 | doi = 10.1021/ja8044376 | url = | issn = | accessdate = 2009-12-25}}</ref>
<ref name="pmid19609444">{{cite journal | author = Brown AK, Taylor RC, Bhatt A, Fütterer K, Besra GS | title = Platensimycin activity against mycobacterial beta-ketoacyl-ACP synthases | journal = Plos One | volume = 4 | issue = 7 | pages = e6306 | year = 2009 | pmid = 19609444 | pmc = 2707616 | doi = 10.1371/journal.pone.0006306 | url = | issn = | accessdate = 2009-12-25}}</ref>
<ref name="pmid17870541">{{cite journal | author = Moda TL, Montanari CA, Andricopulo AD | title = Hologram QSAR model for the prediction of human oral bioavailability | journal = Bioorganic & Medicinal Chemistry | volume = 15 | issue = 24 | pages = 7738–45 | year = 2007 | month = December | pmid = 17870541 | doi = 10.1016/j.bmc.2007.08.060 | url = | issn = | accessdate = 2009-12-20}}</ref>
<ref name="pmid1980">{{cite journal | author = Manzoni P, Rinaldi M, Cattani S, ''et al.'' | title = Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial | journal = [[JAMA]] | volume = 302 | issue = 13 | pages = 1421–8 | year = 2009 | month = October | pmid = 19809023 | doi = 10.1001/jama.2009.1403 | url = http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=19809023 | issn = | accessdate = 2009-10-17}}</ref>
<ref name="pmid19809023">{{cite journal | author = Manzoni P, Rinaldi M, Cattani S, ''et al.'' | title = Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial | journal = [[Journal of the American Medical Association|JAMA]] | volume = 302 | issue = 13 | pages = 1421–1428 | year = 2009 | month = October | pmid = 19809023 | doi = 10.1001/jama.2009.1403 |accessdate = 2009-10-17}}</ref>
*<ref name="pmid16236039">{{cite journal| author=Ando H, Tsuruoka S, Yanagihara H, Sugimoto K, Miyata M, Yamazoe Y et al.| title=Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. | journal=Br J Clin Pharmacol | year= 2005 | volume= 60 | issue= 5 | pages= 494–497 | pmid=16236039
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16236039 | doi=10.1111/j.1365-2125.2005.02462.x | pmc=PMC1884940}}</ref>
*<ref name="pmid12931254">{{cite journal| author=Kajinami K, Takekoshi N, Saito Y| title=Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. | journal=Cardiovasc Drug Rev | year= 2003 | volume= 21 | issue= 3 | pages= 199–215 | pmid=12931254 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12931254}}</ref>
* [[Christof Schaefer ; Doreen Hannemann ; Horst Spielmann ; Klaus Vetter ; Corinna Weber-Schöndorfer]]: ''Arzneiverordnung in Schwangerschaft und Stillzeit'' [[München [u.a.] : Elsevier, Urban & Fischer, 2007.]], ISBN 978-3-437-21332-8
* Christof Schaefer ; Doreen Hannemann ; Horst Spielmann ; Klaus Vetter ; Corinna Weber-Schöndorfer: ''Arzneiverordnung in Schwangerschaft und Stillzeit'' München [u.a.] : Elsevier, Urban & Fischer, 2007., ISBN 978-3-437-21332-8
<ref>Christof Schaefer; et al: ''Arzneiverordnung in Schwangerschaft und Stillzeit'' München : Elsevier, Urban & Fischer, 2007., ISBN 978-3-437-21332-8</ref>
*<ref name="pmid12498010">{{cite journal| author=Flores NA| title=Pitavastatin Nissan/Kowa Yakuhin/Novartis/Sankyo. | journal=Curr Opin Investig Drugs | year= 2002 | volume= 3 | issue= 9 | pages= 1334–1341 | pmid=12498010
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12498010 | quote=Pitavastatin (nisvastatin) is an HMG CoA reductase inhibitor being developed jointly by Nissan, Kowa Kogyo, Novartis and Sankyo for the potential treatment of atherosclerosis and hyperlipidemia.}}</ref>
*<ref name="pmid11060827">{{cite journal| author=Kajinami K, Mabuchi H, Saito Y| title=NK-104: a novel synthetic HMG-CoA reductase inhibitor. | journal=Expert Opin Investig Drugs | year= 2000 | volume= 9 | issue= 11 | pages= 2653–2661 | pmid=11060827
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=11060827 | doi=10.1517/13543784.9.11.2653}}</ref>
*<ref name="pmid18350345">{{cite journal| author=Nishida K, Yamamoto T, Motomura G, Jingushi S, Iwamoto Y| title=Pitavastatin may reduce risk of steroid-induced osteonecrosis in rabbits: a preliminary histological study. | journal=Clin Orthop Relat Res | year= 2008 | volume= 466 | issue= 5 | pages= 1054–1058 | pmid=18350345
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=18350345 | doi=10.1007/s11999-008-0189-4 | pmc=PMC2311459| accessdate = 2009-09-07}}</ref>
{{cite journal |author=Viollet B; Andreelli F; Jørgensen SB ''et al'' |title=The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity |journal=J. Clin. Invest. |volume=111 |issue=1 |pages=91–8 |year=2003 |month=January |pmid=12511592 |pmc=151837 |doi=10.1172/JCI16567 |url=http://www.jci.org/articles/view/16567}}
{{cite journal |last= |first= |author= |authorlink= |coauthors= |date= |year= |month= |day= |title= |trans_title= |journal= |volume= |series= |issue= |page= |pages= |publisher= |location= |issn= |pmid= |pmc= |doi= |bibcode= |oclc= |id= |url= |language= |format= |accessdate= |laysummary= |laysource= |laydate= |quote=}}
<ref name="pmid16267514">{{cite journal | author = Butler D | title = Wartime tactic doubles power of scarce bird-flu drug | journal = [[Nature]] | volume = '''438''' | issue = 7064 | pages = 6 | year = 2005 | month = November | pmid = 16267514 | doi = 10.1038/438006a |accessdate = 2009-11-02}}</ref>
<ref name="pmid17192764">{{cite journal | author = Otto MW, Basden SL, Leyro TM, McHugh RK, Hofmann SG | title = Clinical perspectives on the combination of D-cycloserine and cognitive-behavioral therapy for the treatment of anxiety disorders | journal = CNS Spectrums | volume = 12 | issue = 1 | pages = 51–66, 59–61 | year = 2007 | month = January | pmid = 17192764|url = http://www.cnsspectrums.com/aspx/articledetail.aspx?articleid=954 |accessdate = 2009-11-27}}</ref>
<ref name="pmid17581580">{{cite journal | author = Román-Leshkov Y, Barrett CJ, Liu ZY, Dumesic JA | title = Production of dimethylfuran for liquid fuels from biomass-derived carbohydrates | journal = [[Nature]] | volume = 447 | issue = 7147 | pages = 982–985 | year = 2007 | month = June | pmid = 17581580 | doi = 10.1038/nature05923 | accessdate = 2009-11-27}}</ref>
<ref name="pmid4700880">{{cite journal | author = Dickmann P, Böttcher D, Wittenborg A, Kühn R | title = [Incidents during propanidid anesthesias] | language = German | journal = Die Medizinische Welt | volume = 24 | issue = 12 | pages = 464–7 | year = 1973 | month = March | pmid = 4700880 | doi = | url = | issn = | accessdate = 2009-11-27}}</ref>
<ref name="urlwww.bmg.bund.de">{{cite web | url = http://www.bmg.bund.de/cln_100/SharedDocs/Downloads/DE/Presse/Presse-2009/Presse-2009/btmaendvo,templateId=raw,property=publicationFile.pdf/btmaendvo.pdf | title =Vierundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften (24. BtMÄndV) | author =[[Bundesinstitut für Arzneimittel und Medizinprodukte|BfArM]]| date = | format =PDF, 105 KB | work = | publisher = | pages =12 |accessdate = 2009-11-29}}</ref>
<ref name="pmid1191968">{{cite journal | author = Vecht RJ, Galley R, Goodwin P | title = D C shock: spontaneous reversion to sinus rhythm during anaesthesia with propanidid | journal = [[BMJ (British Medical Journal)|British Medical Journal]] | volume = 4 | issue = 5989 | pages = 143–144 | year = 1975 | month = October | pmid = 1191968 | pmc = 1674830 | accessdate = 2009-12-01}}</ref>
== Literatur ==
*{{cite book | author = Michael Fresenius; Michael Heck | authorlink = | editor = | others = | title = Repetitorium Anästhesiologie: Für die Facharztprüfung und das Europäische Diplom | edition = 5., vollst. aktualisierte Aufl.| language =de | publisher = [[Springer Science+Business Media|Springer-Verlag]] | location = Berlin | year = 2007 | origyear = | pages = 642| isbn = 978-3-540-46575-1 |accessdate = 2009-12-18}}
<ref name=" ISBN 978-3-540-46575-1">{{cite book | author = Michael Fresenius; Michael Heck | authorlink = | editor = | others = | title = Repetitorium Anästhesiologie: Für die Facharztprüfung und das Europäische Diplom (German Edition) | edition = 5., vollst. aktualisierte Aufl.| language =de | publisher = [[Springer Science+Business Media|Springer-Verlag]] | location = Berlin | year = 2007 | origyear = | pages = 642| quote = | isbn = 978-3-540-46575-1 | url = | accessdate = 2009-12-02}}</ref>
<ref name="pmid18325779">{{cite journal | author = Siniscalco D, Giordano C, Fuccio C, ''et al.'' | title = Involvement of subtype 1 metabotropic glutamate receptors in apoptosis and caspase-7 over-expression in spinal cord of neuropathic rats | journal = Pharmacological Research : the Official Journal of the Italian Pharmacological Society | volume = 57 | issue = 3 | pages = 223–233 | year = 2008 | month = March | pmid = 18325779 | pmc = 2424141 | doi = 10.1016/j.phrs.2008.01.007 | url = http://linkinghub.elsevier.com/retrieve/pii/S1043-6618(08)00017-0 | accessdate = 2009-12-05}}</ref>
<ref name="pmid9401972">{{cite journal | author = Lee K, Boden PR | title = Characterization of the inward current induced by metabotropic glutamate receptor stimulation in rat ventromedial hypothalamic neurones | journal = The Journal of Physiology | volume = 504 ( Pt 3) | issue = | pages = 649–663 | year = 1997 | month = November | pmid = 9401972 | pmc = 1159968 | doi = | url = http://www.jphysiol.org/cgi/pmidlookup?view=long&pmid=9401972 | accessdate = 2009-12-05}}</ref>
<ref name="pmid10671907">{{cite journal | author = Gross AS, Eichelbaum M, Mörike K, Mikus G | title = Pharmacokinetics and pharmacodynamics of R- and S-gallopamil during multiple dosing | journal = British Journal of Clinical Pharmacology | volume = 49 | issue = 2 | pages = 132–138 | year = 2000 | month = February | pmid = 10671907 | pmc = 2014898 |accessdate = 2009-12-09}}</ref>
<ref name="pmid17107647">{{cite journal | author = Soler E, Thépot D, Rival-Gervier S, Jolivet G, Houdebine LM | title = Preparation of recombinant proteins in milk to improve human and animal health | journal = Reproduction, Nutrition, Development | volume = 46 | issue = 5 | pages = 579–588 | year = 2006 | pmid = 17107647 | url = http://rnd.edpsciences.org/articles/rnd/pdf/2006/06/r6505.pdf | accessdate = 2009-12-12}}</ref>
<ref name="pmid19966941">{{cite journal | author = Handorean AM, Yang K, Robbins EW, Flaig TW, Iczkowski KA | title = Silibinin suppresses CD44 expression in prostate cancer cells | journal = American Journal of Translational Research | volume = 1 | issue = 1 | pages = 80–86 | year = 2009 | pmid = 19966941 | pmc = 2776293 | accessdate = 2009-12-13}}</ref>
<ref name="pmid18567676">{{cite journal | author = Holbrook SP, Quinn A | title = An unusual explanation for low oxygen saturation | journal = British Journal of Anaesthesia | volume = 101 | issue = 3 | pages = 350–353 | year = 2008 | month = September | pmid = 18567676 | doi = 10.1093/bja/aen183 | url = http://bja.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=18567676 | issn = | accessdate = 2009-12-18}}</ref>
<references />
Es ist außerdem Bestandteil von [[Günzburgs Reagenz]] – einer alkoholischen Lösung von Phloroglucin und [[Vanillin]] zum qualitativen Nachweis der freien [[Salzsäure]] im [[Magensaft]].
[[Datei:Copaxone Injection Site Reaction.JPG|hochkant=1|mini|Injection Site Reaction - Upper Left Arm]]
[[Datei:Caffeine citrate.svg|links|mini|hochkant=1|Struktur von Coffeincitrat]]
Coffeincitrat, Coffein-Citronensäure-Gemisch (ASK),
[[Nomenklatur (Chemie)|Nomenklatur]] nach [[IUPAC]]: 1,3,7-Trimethyl-3,7-dihydro-2H-purin-2,6-dion + 2-Hydroxypropan-1,2,3-tricarbonsäure, hat die [[Summenformel]] C<sub>14</sub>H<sub>18</sub>N<sub>4</sub>O<sub>9</sub>, eine [[molare Masse]] von 386,31 [[Gramm|g]]·[[mol]]<sup>−1</sup> und die [[CAS-Nummer]] 69-22-7. Es ist ein weißes [[kristallin]]es Pulver, löslich 1:4 in heissem Wasser (Dissoziation), 1:25 in Ethanol 96 %.<ref name="Martindale">Sean Sweetman (Hrsg.): ''Martindale: The Complete Drug Reference, 35th Edition: Book and CD-ROM Package''. Pharmaceutical Press, ISBN 978-0-85369-704-6</ref> Der [[Anatomisch-Therapeutisch-Chemisches Klassifikationssystem|ATC-Code]] ist ''N06BC01''.
{{Absatz|links}}
[[WP:FAS]]
* '''Handelsnamen''' sollten in einem separaten Abschnitt – alphabetisch sortiert und durch Kommata getrennt – nach den Einzelnachweisen stehen, dazu sollte stehen in welchem Land der Name gilt (A) (CH) (D). Ist ein Medikament im deutschsprachigen Raum nur unter einem Markennamen erhältlich, kann dieser direkt im ersten Satz hinter dem Lemma erwähnt werden.
[[Wikipedia:Redaktion Medizin/Leitlinien#M. Aufführen bekannter Persönlichkeiten|Aufführen bekannter Persönlichkeiten]]
#[[Handelsname]]n können als Weiterleitung auf den Arzneistoffartikel angelegt werden. Dort sollen diese Weiterleitungen alphabetisch sortiert, durch Kommata getrennt, unter einer Überschrift „Handelsnamen“ am Ende des Artikels aufgeführt sein. Gegebenenfalls sind Monopräparate und Kombinationspräparate getrennt aufzulisten. Wenn das Arzneimittel im deutschsprachigen Raum nur unter einem Handelsnamen erhältlich ist, soll dieser in der Einleitung erwähnt werden. Das gesonderte Anführen in der [[Wikipedia:Formatvorlage Arzneistoff]] ist damit verzichtbar.
{{Rechtshinweis illegale Droge Anlage 2|Meprobamat}}
{{cite book |author=Davis, Neil M. |title=Medical abbreviations: 15, 000 conveniences at the expense of communications and safety |publisher=N.M. Davis Associates |location=Huntingdon Valley, Pa |year=2001 |pages= |isbn=0-931431-10-7 |oclc= |doi= |accessdate=}}
{{cite book | author = Davis, Neil M. | authorlink = | editor = | others = | title = Medical abbreviations: 15, 000 conveniences at the expense of communications and safety | edition =10. | language = en| publisher = N.M. Davis Associates | location = Huntingdon Valley, Pa | year = 2001 | pages = | quote = | isbn = 0-931431-10-7 | oclc = |accessdate = }}
<ref name="pmid18809554">{{cite journal | author = Nakaminami H, Noguchi N, Ikeda M, ''et al.'' | title = Molecular epidemiology and antimicrobial susceptibilities of 273 exfoliative toxin-encoding-gene-positive Staphylococcus aureus isolates from patients with impetigo in Japan | journal = Journal of Medical Microbiology | volume = 57 | issue = Pt 10 | pages = 1251–1258 | year = 2008 | month = October | pmid = 18809554 | doi = 10.1099/jmm.0.2008/002824-0 | accessdate = 2009-08-07}}</ref>
<ref name="vetpharm">{{cite web |url=http://www.vetpharm.uzh.ch/wir/00006610/4221__F.htm |title=Wirkstoffdaten für Pergolid | author=Institut für Veterinärpharmakologie und -toxikologie der UNIVERSITÄT ZÜRICH |language=De |accessdate = 2010-08-06}}</ref>
<references />
{{ISSN|0385-5414}}
03855414
<ref>{{cite web | url = http://www.bohren-nein-danke.de/upload/files/download//z_downloads_1_ICON_WisDok_deutsch.pdf | title =Mikroinvasive Behandlung der Karies durch Infiltration von Kunststoffen| author = | date =| format = PDF 2,19 MB| work =Aus der Wissenschaft in die Praxis, eine Studienübersicht | publisher = | pages = 42| language =de | accessdate = 2009-09-24}}</ref>
<references />
{{cite web | url = http://edoc.ub.uni-muenchen.de/6593/1/Boos_Dominik.pdf | title = Separase: Regulation, Funktion und neue Substrate | author = Diplom-Biologe Dominik Boos| date = März 2007| format = PDF| work =Dissertation der Fakultät für Biologie der Ludwig-Maximilians-Universität München | publisher = | pages = | language = | accessdate = 2009-05-18}}
{{Zitat
|Text=Aus dem Lat. Morsellus. dem Diminut von Morsus, welches in den mittlern Zeiten sehr oft für ein kleines Stück überhaupt vorkommt; Franz. Morceau.
ein in den Apotheken übliches Wort, eine Arzeney zu bezeichnen, welche mit Zucker vermischt in kleinen festen länglichen viereckigen Stücken bereitet wird, und wovon die '''Magen–Morsellen''' eine Art sind.
Die '''Morsellen''' und '''Rotulen''' sind eigentlich harte Latwergen, bey denen die Pulver, frische und eingemachte Früchte, mit einem so stark eingekochten Zucker vermischt werden, der, nachdem er erkaltet, hart wird; sie unterscheiden sich bloß dadurch, daß erstere meistentheils aus mehrerem und gröberem Pulver bestehen und von viereckiger Form sind; letztere aber weniger, doch allemahl feines Pulver enthalten und rund sind. Der Zucker zu diesen Arzeneyen muß ungleich härter, als beym Zuckersafte, eingekocht seyn. Man löset ihn nähmlich in wenigem Wasser auf (auf 4 Pfund Zucker sind 12 Unzen Wasser zureichend), und nachdem der Schaum abgenommen ist, läßt man ihn so lange über dem Feuer stehen, bis, daß wenn man einige Tropfen von dem Spatel in einer geringen Höhe fallen läßt, diese Tropfen einen sehr langen oder dünnen Faden ziehen, oder, wenn man etwas von dem Spatel mit einer Geschwindigkeit in die Luft wirft, dasselbe als eine höchst dünne feine Haut oder Spinnewebe erscheinet. Wenn er diese Dicke hat, so sagt man, er sey ad consistentiam tabulandi gekocht. Man nimmt ihn sogleich vom Feuer, und rührt ihn in der Pfanne mit einem Spatel so lange, bis er an den Seiten undurchsichtig zu werden anfängt, welches man das Absterben des Zuckers nennt. Dieses Absterben wird befördert, wenn ihm gleich anfangs, sobald er vom Feuer genommen worden, etwas starker Weingeist zugesetzt wird. Zuletzt schüttet man die Species zu, und nachdem man sie gut durchmischt hat, gießt man die Masse, wenn es Morsellen werden sollen, in eine befeuchtete hölzerne Form aus, und nachdem sie etwas erkaltet, wird sie mit einem Messer in längliche Vierecke zerschnitten. Sollen es aber '''Rotulen''' werden, so läßt man den Zucker tropfenweise aus der Pfanne auf ein Blech fallen (welches man das '''Rotuliren''' nennt), kalt werden, damit sie erhärten, und nachher macht man das Blech wärmlich, da sie sich denn leicht abschieben lassen.
Wenn zu den Morsellen viele und dabey feine Pulver kommen sollen, so müssen diese, sobald der Zucker vom Feuer abgenommen wird, zugemischet und auch eher ausgegossen werden, ausgenommen in dem Fall, wenn die Pulver mit Spießglanz oder Eisenfeil gemischt sind. Was das Verhältniß der Pulver oder Species zu diesen Bereitungen anbetrifft, so kann man hier eben nichts gewisses festsetzen. Auf ein Pfund Zucker kann man zu den Morsellen 1–4 Unzen Species nehmen; zu den Rotulen aber, denen allezeit feine Pulver beygemischt werden, muß eine geringere Menge genommen werden, weil es mit dem Rotuliren allezeit ungleich langsamer hergeht, und der Zucker zu geschwind absterben möchte. Geschieht dieses allenfalls, so tröpfelt man zu dem übrigen einige Tropfen Wasser zu, erwärmt es etwas und fährt dann mit dem Rotuliren fort.
Diejenigen Morsellen und Rotulen aber, zu denen ein säuerlicher Saft, als Zitronen– und Berberbeerensaft genommen wird, gehen von der vorher angezeigten Bereitung ab. Wollte man diese, so wie jene, mit den sauren Säften kochen, so würden sie nie können trocken erhalten werden. Gewöhnlich werden sie auf diese Art verfertiget, daß man den Zucker fein stoßen und über gelindem Feuer an sich erwärmen läßt, und alsdenn so wenig als möglich Saft zumischt, um ohne alles Kochen die Consistenz zu erhalten. Auf ein Pfund Zucker nimmt man höchstens zwey Unzen Saft. Sonst aber gerathen die Zitronen–Morsellen sehr gut, wenn man den Zucker mit Wasser zu einer stärkern Consistenz, als gewöhnlich, einkocht, und dann, wenn er unter dem Rühren zu ersterben anfängt, den Zitronensaft zumischet und geschwinde ausgießt. Um die '''Manna–Morsellen''' (Manna tabulata) ohne Zucker zu machen, wird die Manna in höchst wenigem Wasser aufgelöst, warm durchgeseihet und zu Morsellen ausgegossen. Kommt etwas zu vieles Wasser hinzu, so gerinnt sie nicht, sondern bleibt stets zähe und klar.
|Autor=S. Hagen
|Quelle=''Lehrbuch der Apothekerkunst''; 3te Aufl. Königsberg und Leipzig 1786. S. 855–857}}
*{{cite book |author=Mario Gmür |title=Die Unfähigkeit zu zweifeln |publisher=Klett Cotta Verlag |location=Stuttgart |year=2006 |pages=336 |isbn=3-608-94093-6 |accessdate=}}
* Mario Gmür: ''Die Unfähigkeit zu zweifeln''. Klett Cotta Verlag, ISBN 978-3-608-94093-0
ISBN 978-3-89599-166-0
{| class="wikitable" style="text-align:right"
| [[Datei:Ampicillin-2D-skeletal.png|200px]] || [[Datei:Sulbactam.svg|100px]] || [[Datei:Sultamicillin schematic.svg|220px]]
|-
| [[Strukturformel]] von [[Ampicillin]] || Strukturformel von [[Sulbactam]] || Strukturformel von [[Sultamicillin]], blau = Ampicillin orange = Sulbactam
|}
*{{Literatur
|Autor=Corina Raab
|Titel=Illegale Drogen: Konstruktion eines modularen Inventars zur Erfassung von kognitiv-behavioralen Risiko- und Protektivfaktoren
|Verlag=Vdm Verlag Dr. Müller
|Datum=2008
|ISBN=978-3-8364-7241-8
|Seiten=348}}
Andrew Morgan, Christine Cofer & Dennis L Stevens: Iclaprim, a novel dihydrofolate reductase inhibitor for skin and soft tissue infections. Future Microbiol. (2009), 4(2): 131-143
Morgan A, Cofer C, Stevens DL.:''Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.'' Future Microbiol. (2009) Mar;4:131–144 PMID 19257839 [[doi:10.2217/17460913.4.2.131]]
[http://toolserver.org/~diberri/cgi-bin/templatefiller/ templatefiller]
[https://securesearch.acros.com/msds?for=acros&sup=acros&lang=DE&search=127960010 SDB von AMP]
Hartmut Göbel, Die Kopfschmerzen – Ursachen, Mechanismen, Diagnostik und Therapie in der Praxis, Springer-Verlag, Berlin, Heidelberg, New York 2003, 2. Auflage, ISBN 3-540-61160-6
[http://toolserver.org/~magnus/deep_insight.php?category=Arzneistoff&redirects=1 Arzneistoff-Weiterl.]
[http://www.ncbi.nlm.nih.gov/sites/entrez?term=9005-71-4%7E%5Bsynonym%5D&cmd=search&db=pcsubstance Hilft das weiter?]
<ref name="Martindale">Sean Sweetman (Hrsg.): ''Martindale: The Complete Drug Reference, 35th Edition: Book and CD-ROM Package''. Pharmaceutical Press, ISBN 978-0-85369-704-6</ref>
* <ref>Sean Sweetman (Hrsg.): ''Martindale: The Complete Drug Reference, 35th Edition: Book and CD-ROM Package''. Pharmaceutical Press, ISBN 0-85369-704-3</ref>
<ref>{{Literatur |Autor=H.N. Morse |Titel=Ueber eine neue Darstellungsmethode der Acetylamidophenole |Sammelwerk=Berichte der deutschen chemischen Gesellschaft |Band=232 |Nummer=11 |Datum=1878 |Seiten=232–233 |DOI=10.1002/cber.18780110151}}</ref>.
<ref>{{cite web|url=http://www.journalonko.de/aktuellview.php?id=1244|title=Therapiemanagement: Capecitabin und das Hand-Fuß-Syndrom|accessdate=2009-04-13|author=Hendrik-Tobias Arkenau|year=2006|format=html|language=deutsch}}</ref>
<ref name="fi">[http://www.drugs.com/pro/levobunolol.html ''FDA-Fachinformation für Levobunolol bei Drugs.com'']</ref>
*[http://www.roche.de/datenblaetter/index.htm?sid=3bb4434f49bc954f942d1d3e27c3a195&country=DE&lang=DE&material_no=10831620103&search_mat=Suchen+%2F+Search&lang=DE&country=DE MSDS]
<ref>Robyn J Barst:''A review of pulmonary arterial hypertension: role of ambrisentan'' Vasc Health Risk Manag. 2007 March; 3(1): 11–22.[http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=17583171 Volltext (HTML)] [http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1994051&blobtype=pdf Volltext (PDF 1,1 MB)] PMID 17583171</ref>
* [http://www.arznei-telegramm.de/db/akb.php3?&knr=&nummer=Magaldrat Magaldrat bei arznei-telegramm<sup>®</sup>]
*[http://sunset-clause.dimdi.de/muster/OBF1722AC6A601C7D29E.rtf Mustertext für Magaldrat, Stand 2003]
[[Spezial:Beiträge/Inkogn!to|5 Minuten]]
<ref name="entrez">{{cite web | title = Entrez Gene: PDPN podoplanin| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=10630| accessdate = }}</ref>
<ref name="fi">[http://sunset-clause.dimdi.de/muster/OBF1A5DC811201C7D2A1.rtf ''Fachinformation (Mustertext des BfArM für Simeticon), Stand: 21. Dezember 2000'']</ref>
<ref name="pmid19257839">{{cite journal |author=Morgan A, Cofer C, Stevens DL |title=Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections |journal=[[Future Microbiology]] |volume=4 |issue=2 |pages=131–44 |year=2009 |month=March |pmid=19257839 |doi=10.2217/17460913.4.2.131 |url=http://www.futuremedicine.com/doi/abs/10.2217/17460913.4.2.131?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dncbi.nlm.nih.gov |accessdate=2009-04-24}}</ref>
<ref name=" ISBN 0-911910-00-X">{{cite book | author = O'Neil, Maryadele J. | authorlink = | editor = | others = | title = The Merck index: an encyclopedia of chemicals, drugs, and biologicals | edition = | language = | publisher = Merck | location = Rahway, N.J., U.S.A | year = 2006 | origyear = | pages = | quote = | isbn = 0-911910-00-X | oclc = | doi = | url = | accessdate = }}</ref>
<ref name="pmid16424933">{{cite journal | author = Brielmaier BD | title = Eszopiclone (Lunesta): a new nonbenzodiazepine hypnotic agent | journal = [[Proceedings (Baylor University. Medical Center)]] | volume = 19 | issue = 1 | pages = 54–9 | year = 2006 | month = January | pmid = 16424933 | pmc = 1325284 | doi = | url = http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1325284| issn = | accessdate = 2009-04-26}}</ref>
<references />
{{Wiktionary|Euthanasie}}
* [http://www.klinische-toxikologie.de/fileadmin/DOKUMENTE/Mitteilungen/GfKT_Mitteilung_Paracetamol_2008-03-20.pdf Vergiftungen mit Paracetamol in DE]
* [http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=%28%22sildenafil%22%5BSubstance+Name%5D+OR+%22sildenafil%22%5BAll+Fields%5D%29+AND+%22loattrfree+full+text%22%5BFilter%5D Sildenafil in Pubmed]
<ref>E. J. Ariëns: ''Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology'' Eur J Clin Pharmacol. 1984;26(6):663–668. [http://www.springerlink.com/content/ng657086x6u73p44/fulltext.pdf Volltext (PDF)] PMID 6092093</ref>
<ref>Neera Ghaziuddin et al.:''Central Serotonergic Effects of m-Chlorophenylpiperazine (mCPP) among Normal Control Adolescents'' Neuropsychopharmacology (2003) 28, 133–139. [http://www.nature.com/npp/journal/v28/n1/full/1300006a.html Volltext (HTML)][http://www.nature.com/npp/journal/v28/n1/pdf/1300006a.pdf Volltext (PDF)] PMID 12496949</ref>
<ref>Topaloglu et al.:''TAC3 and TACR3 Mutations in Familial Hypogonadotropic Hypogonadism Reveal a Key Role for Neurokinin B in the Central Control of Reproduction.'' Nat Genet. 2008 Dec 11. [Epub ahead of print] [http://www.nature.com/ng/journal/vaop/ncurrent/extref/ng.306-S1.pdf Supplementary Notes (PDF)] PMID 19079066 [[doi:10.1038/ng.306]]</ref>
<ref>N.M. Page et al.:''Gene regulation of neurokinin B and its receptor NK3 in late pregnancy and pre-eclampsia'' Molecular Human Reproduction 2006 12(7):427–433 [http://molehr.oxfordjournals.org/cgi/content/full/12/7/427#top Volltext (HTML)] [http://molehr.oxfordjournals.org/cgi/reprint/12/7/427.pdf Volltext (PDF)] PMID 16709596</ref>
<ref>Huxtable RJ, Schwarz SK.:''The isolation of morphine--first principles in science and ethics'' Mol Interv. 2001 Oct;1(4):189–191. [http://molinterv.aspetjournals.org/cgi/content/full/1/4/189 Volltext (HTML)] [http://molinterv.aspetjournals.org/cgi/reprint/1/4/189.pdf Volltext (PDF)] PMID 14993340</ref>
<ref name="fi">[http://sunset-clause.dimdi.de/muster/OBF11616FF0E01C7D291.rtf ''Fachinformation für: Gallopamilhydrochlorid''] (Mustertext des [[Bundesinstitut für Arzneimittel und Medizinprodukte|BfArM]]), Stand: 1. April 2004</ref>
<ref>Heiner K. Berthold, MD, PhD et al.:''Effect of Policosanol on Lipid Levels Among Patients With Hypercholesterolemia or Combined Hyperlipidemia – A Randomized Controlled Trial'' JAMA. 2006;295(19):2262–2269 [http://jama.ama-assn.org/cgi/content/full/295/19/2262 Volltext (HTML)] [http://jama.ama-assn.org/cgi/reprint/295/19/2262.pdf Volltext (PDF)] PMID 16705107 [[doi:10.1001/jama.295.19.2262]]</ref>
<ref>{{cite journal |author=Peppard WJ, Schuenke CD |title=Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections |journal=Curr Opin Investig Drugs |volume=9 |issue=2 |pages=210–25 |year=2008 |month=February |pmid=18246524 |doi= |url=}}</ref>
<ref name="pmid17222320">{{cite journal | author = Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS | title = Low-dose naltrexone therapy improves active Crohn's disease | journal = [[The American Journal of Gastroenterology]] | volume = 102 | issue = 4 | pages = 820–828 | year = 2007 | month = April | pmid = 17222320 | doi = 10.1111/j.1572-0241.2007.01045.x | url = http://dx.doi.org/10.1111/j.1572-0241.2007.01045.x | accessdate = 2009-05-12}}</ref>
== Klinische Angaben ==
=== Anwendungsgebiete (Indikationen) ===
schwere polymikrobielle Infektionen: Infektionen des Gastrointestinaltraktes, Infektionen der
unteren Atemwege, gynäkologische Infektionen, Sepsis, urogenitale Infektionen, Infektionen der
Knochen und Gelenke, Infektionen der Haut und Weichteile, Endokarditis;
=== Verwendung als Orphan-Arzneimittel ===
Bei [[Therapie|therapeutischen]] [[Dosis|Dosierungen]] von Cetirizin wurden im Zusammenhang mit der Einnahme von [[Ethanol|Alkohol]] – bei einer [[Plasmaspiegel|Plasmakonzentration]] von 0,5 Gramm/Liter – keine klinisch signifikanten [[Arzneimittelwechselwirkung]]en festgestellt. Dennoch ist bei gleichzeitiger Einnahme mit Alkohol Vorsicht geboten.
Auf Grund der Pharmakokinetik, Pharmakodynamik und des Verträglichkeitsprofils von Cetirizin sind keine Wechselwirkungen mit diesem Antihistaminikum zu erwarten. Tatsächlich wurden weder pharmakodynamische noch signifikante pharmakokinetische Wechselwirkungen in durchgeführten Interaktionsstudien berichtet, insbesondere nicht mit [[Pseudoephedrin]] und [[Theophyllin]] (400 mg/Tag). Das Ausmaß der [[Resorption]] von Cetirizin wird durch [[Ernährung|Nahrungsaufnahme]] nicht vermindert, obwohl die Resorptionsgeschwindigkeit herabgesetzt ist.
Seit dem 1. September 2009 ist das erste zugelassene Fentanyl-[[Nasenspray]] – (''Instanyl<sup>®</sup>'' von [[Nycomed]]) – gegen Durchbruchschmerz auf dem europäischen Markt erhältlich. Das Medikament ist indiziert für die Behandlung von Durchbruchschmerzen bei Erwachsenen, die bereits eine Opioid-Basistherapie gegen ihre chronischen Tumorschmerzen erhalten.
<ref>[http://www.ema.europa.eu/humandocs/Humans/EPAR/silodyx/silodyx.htm ''European Public Assessment Report for Silodyx<sup>®</sup>''] auf der Website der [[Europäische Arzneimittelagentur|Europäischen Arzneimittelagentur]], Abgerufen am 20. Juni 2010.</ref>
<ref>[http://www.ema.europa.eu/humandocs/Humans/EPAR/urorec/urorec.htm ''European Public Assessment Report for Urorec<sup>®</sup>''] auf der Website der [[Europäische Arzneimittelagentur|Europäischen Arzneimittelagentur]], Abgerufen am 20. Juni 2010.</ref>
==== Chemische und pharmazeutische Angaben ====
[[Datei:Caffeine citrate.svg|mini|links|Struktur von Coffeincitrat]]
Coffeincitrat, Coffein-Citronensäure-Gemisch (ASK),
[[Nomenklatur (Chemie)|Nomenklatur]] nach [[IUPAC]]: ''1,2,3-Propanetricarboxylic acid, 2-hydroxy-, mixt. with 3,7-dihydro-
1,3,7-trimethyl-1H-purine-2,6-dione'', hat die [[Summenformel]] C<sub>14</sub>H<sub>18</sub>N<sub>4</sub>O<sub>9</sub>, eine [[molare Masse]] von 386,31 [[Gramm|g]]·[[mol]]<sup>−1</sup> und die [[CAS-Nummer]] 69-22-7. Es ist ein weißes [[kristallin]]es Pulver, löslich 1:4 in heissem Wasser (Dissoziation), 1:25 in Ethanol 96 %. Der [[Anatomisch-Therapeutisch-Chemisches Klassifikationssystem|ATC-Code]] ist ''N06BC01''
== Pharmakologische Eigenschaften ==
=== Wirkungsmechanismus (Pharmakodynamik) ===
Cilastatin ist ein spezifischer Hemmer des Enzyms Dehydropeptidase-I und ein wirksamer Hemmstoff des Imipenem-Metabolismus, so dass die gleichzeitige Anwendung von Imipenem und Cilastatin es ermöglicht, therapeutische, antibakteriell wirksame Imipenem-Spiegel sowohl im Urin als auch im Plasma zu erreichen. Das Verhältnis von Cilastatin und Imipenem beträgt bei allen Medikamenten 1:1.
=== Aufnahme und Verteilung im Körper (Pharmakokinetik) ===
;Distribution
Nach einer 20minütigen [[intravenös]]en Infusion betrugen die Spitzenplasmawerte für Cilastatin 21 bis 26 μg/ml (Mittelwert 22 μg/ml) bei der 250 mg-Dosis, nach einer 500 mg-Dosis 21 bis 55 μg/ml (Mittelwert 42 μg/ml) und 56 bis 88 μg/ml (Mittelwert 72 μg/ml) für die 1000 mg-Dosis.
Die [[Proteinbindung|Plasmaproteinbindung]] von Cilastatin beträgt ungefähr 40 %.
Der Wirkstoff passiert die [[Plazenta#Plazentaschranke|Plazentaschranke]] und verteilt sich im [[Nabelschnurblut]] und in der [[Fruchtwasser|Amnionflüssigkeit]] (Fruchtwasser). Ob er in die [[Muttermilch]] übertritt, ist nicht bekannt.
;[[Stoffwechsel|Metabolismus]] und [[Elimination (Pharmakokinetik)|Elimination]]
Die [[Plasmahalbwertszeit]] von Cilastatin beträgt circa eine Stunde. Etwa 70–80 % des verabreichten Cilastatins wurde unverändert im Urin innerhalb von 10 Stunden wiedergefunden. Nach diesem Zeitpunkt wurde kein weiteres Cilastatin mehr im Urin festgestellt. Etwa 10 % wurden als N-Acetyl-[Metabolit]] nachgewiesen, dessen hemmende Aktivität gegen die Dehydropeptidase-I vergleichbar mit der von Cilastatin ist. Die Aktivität der Dehydropeptidase-I in der Niere erreicht kurz nach der Elimination von Cilastatin aus dem Blut wieder die Normalwerte. Bei gleichzeitiger Anwendung mit [[Probenecid]] verdoppelten sich [[Plasmaspiegel]] und Halbwertszeit von Cilastatin, die Urinrecovery von Cilastatin blieb unbeeinflusst.
<ref name="fda">{{cite web | url =http://www.cdc.gov/h1n1flu/eua/Final%20HCP%20Fact%20sheet%20Peramivir%20IV_CDC.pdf | title =Peramivir EUA, Fact Sheet for HCP Authorized by FDA on October 23, 2009 | format =PDF | pages = 42| language =en | accessdate = 2009-11-04}}</ref>
<!-- === Toxikologie === -->
== Sonstige Informationen ==
<!-- === Chemische und pharmazeutische Informationen ===
-->
<!-- === Geschichtliches ===
-->
<references />
== Weblinks ==
{{Wiktionary|Paracetamol}}
{{Commonscat|Paracetamol|Paracetamol}}
[http://www.maybridge.com/portal/alias__Rainbow/lang__en/tabID__148/DesktopDefault.aspx] Eingabe BTB13290
*[http://www.msd.de/htbin/msdmanual.pl?m=11-12-2 Polycythaemia Vera] in [[Merck Manual of Diagnosis and Therapy]] Professional Edition
<ref name="FDA">{{cite web |url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175046.htm |title=FDA Approves New Cholesterol-Lowering Drug |format= |accessdate=2009-09-04}}</ref>
<references />
== MeshName ==
{{MeshName|Enzyme+Multiplied+Immunoassay+Technique}}
{{MeshName|spinocerebellar+ataxia+13+protein,+human}}
* {{MeshName|M2+protein,+Influenza+A+virus}}
[[Vorlage:MeshName]]
{{Rechtshinweis illegale Droge Anlage 2|Vinylbital}}
[http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=sca13 Spinocerebellar Ataxia Type13 bei GeneReviews]
<ref name="ChemIDplus">{{ChemID|815610-63-0}}</ref>
<references />
[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=605259 Spinocerebellar Ataxia Type13 bei OMIM]
<math>C_{max}</math>
<math>t_{lag}</math>
<math>t_{max}</math>
<math>C_{min}</math>
<math>t_{1/2}</math>
[[Wikipedia:WikiProjekt Vorlagenauswertung/news]]
{{cite journal|author = L. Dupont, O. Dideberg, J. Lamotte-Brasseur et L. Angenot| title = Structure cristalline et moléculaire de la picrotoxine, C<sub>15</sub>H<sub>16</sub>O<sub>6</sub>.C<sub>15</sub>H<sub>18</sub>O<sub>7</sub>|journal = Acta Cryst.|year = 1976| volume = B32| pages = 2987–2993|language = French|doi = 10.1107/S0567740876009424|accessdate = 2009-05-19}}
== Weblinks ==
* {{cite journal |author=Ehrenberger K, Benkoe E, Felix D |title=Suppressive action of picrotoxin, a GABA antagonist, on labyrinthine spontaneous nystagmus and vertigo in man |journal=Acta Otolaryngol. |volume=93 |issue=3-4 |pages=269–73 |year=1982 |pmid=7064710 |doi=10.3109/00016488209130882}}
*[http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=bnchm.section.1181 Basic Neurochemistry: GABA Receptor Physiology and Pharmacology]
[[doi:10.1152/jn.00300.2004]]
*[[doi:10.1007/s00103-009-0771-2]]
[[doi:10.1159/000209090]]
[[doi:10.1107/S0567740876009424]]
DOI:10.1159/000209090
[http://toolserver.org/~magnus/commonshelper.php Nach Commons verschieben]
[[doi:10.1002/pauz.200600221]]
[http://toolserver.org/~daniel/WikiSense/CategoryIntersect.php?wikilang=de&wikifam=.wikipedia.org&basecat=ATC-Code&basedeep=2&mode=ts&templates=ATC&untagged=on&go=Scannen&userlang=de ATC-Scan]
[http://tools.wikimedia.de/~daniel/WikiSense/CategoryIntersect.php?wikilang=de&wikifam=.wikipedia.org&basecat=Arzneistoff&basedeep=6&mode=ts&templates=Infobox+Arzneistoff&go=Scannen&userlang=de Alte Infoboxen]
<ref>Feenstra J. et al. ''Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant'' Eur J Endocrinol. 2006 Jun;154(6):805-6 PMID 16728538 [http://eje-online.org/cgi/reprint/154/6/805.pdf Full Text (PDF)]</ref>
<ref>M. Schachter et al.: ''Fluvoxamine and clomipramine in the treatment of cataplexy'' J Neurol Neurosurg Psychiatry. 1980 February;43(2):171–174 PMID 6766990[http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=490494&blobtype=pdf Volltext (PDF)]</ref>
<ref>Gustafson RA. et al.:''Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans.'' Clin Chem. 2003 Jul;49(7):1114-24. PMID 12816908 [http://www.clinchem.org/cgi/content/full/49/7/1114 Volltext HTML]</ref>
<ref>Yuan CS. et al.:''Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial.'' J Pharmacol Exp Ther. 2002 Jan;300(1):118-23. PMID 11752106 [http://jpet.aspetjournals.org/cgi/content/full/300/1/118 Volltext HTML]</ref>
<ref>Coen A. et al. ''TRIMETHOPRIM–SULFAMETHOXAZOLE (CO-TRIMOXAZOLE) FOR THE PREVENTION OF RELAPSES OF WEGENER’S GRANULOMATOSIS'' N Engl J Med 1996; 335:1769-1770, Dec 5, 1996 PMID 8637536 [http://content.nejm.org/cgi/reprint/335/1/16.pdf Full Text (PDF)]</ref>
<ref>Singleton PA. et al. ''Attenuation of Vascular Permeability by Methylnaltrexone Role of mOP-R and S1P3 Transactivation'' Am J Respir Cell Mol Biol Vol 37. pp 222–231, 2007 [http://ajrcmb.atsjournals.org/cgi/reprint/37/2/222.pdf Volltext (PDF)] PMID 17395891</ref>
<ref name="EUSPC">TOVIAZ<sup>®</sup>: [http://www.emea.europa.eu/humandocs/PDFs/EPAR/toviaz/emea-combined-h723de.pdf Zusammenfassung der Merkmale des Arzneimittels, Stand: Oktober 2008] auf der Website der [[Europäische Arzneimittelagentur|Europäischen Arzneimittelagentur]](EMEA)</ref>
<ref>James G. MacLean:''Treatment of Acne with Prothipendyl'' Can Med Assoc J. 1961 February 25; 84(8): 427–430 PMID 13764951 [http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1939286&blobtype=pdf Full Text (PDF)]</ref>
<ref>Fleetwood JF:''The Treatment of Mental Symptoms in the Aged with PROTHIPENDYL (TOLNATE)'' J Coll Gen Pract. 1964 Sep;8:262-6 PMID 14199907[http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1878127&blobtype=pdf Full Text (PDF)]</ref>
<ref>ALLEN B. et al.: ''THE ANTISIALOGOGUE EFFECT OF PHENOTHIAZINE DERIVATIVES: COMPARISON OF PROMAINE, LEVOMEPROMAZINE, TRIFLUOPERAZINE, PROCLORPERAZINE, METHDILAZINE AND PROTHIPENDYL'' Anesthesiology. 21(3):260-262, May/June 1960 [http://www.anesthesiology.org/pt/re/anes/pdfhandler.00000542-196005000-00005.pdf;jsessionid=LNJRwQgT0kgzZDyzk5LhRYWPsQ1ppmNTQyCQkFtwzgq2xyn6W1qL!612563345!181195628!8091!-1 Full Text (PDF)]</ref>
<ref>Hagedorn HW. et al. ''Prothipendyl: detection and elimination in the horse--a case report'' Dtsch Tierarztl Wochenschr. 1996 Apr;103(4):125-7 PMID 8925772</ref>
<ref>Tzschentke TM et al.:''(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.'' J Pharmacol Exp Ther. 2007 Oct;323(1):265-76. Epub 2007 Jul 26. [http://jpet.aspetjournals.org/cgi/content/full/323/1/265 Volltext (HTML)] [http://jpet.aspetjournals.org/cgi/reprint/323/1/265.pdf Volltext (PDF)]
PMID 17656655</ref>
<ref>Karavitaki N. et al. ''Pegvisomant: a new treatment modality for acromegaly'' Hormones (Athens). 2004 Jan-Mar;3(1):27-36. PMID 16982575 [http://hormones.gr/preview.php?c_id=71 Full Text]</ref>
<ref>{{AWMF|http://www.uni-duesseldorf.de/awmf/ll/013-035.htm|Phototoxische und photoallergische Reaktionen|S1|Deutschen Dermatologischen Gesellschaft|2/2007}}</ref>
<ref>{{AWMF|http://www.uni-duesseldorf.de/AWMF/ll/025-009.htm|Medulloblastom im Kindes- und Jugendalter|S1|Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH)|10/2008}}</ref>
<ref>Schwahn BC. et al. ''Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria'' Br J Clin Pharmacol. 2003 Jan;55(1):6-13. PMID 12534635 [http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1884185&blobtype=pdf Full Text PDF]</ref>
<ref>Schwahn BC. et al. ''Betaine rescue of an animal model with methylenetetrahydrofolate reductase deficiency'' Biochem J. 2004 Sep 15;382(Pt 3):831-40. PMID 15217352 [http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1133958&blobtype=pdf Full Text PDF]</ref>
== Einzelnachweise ==
<references />
{{Wikibooks|Pharmakologie und Toxikologie: Magen-Darm-Trakt#Entschäumer|Pharmakologie und Toxikologie: Magen-Darm-Trakt-Entschäumer}}
{{Wikibooks|Pharmakologie und Toxikologie: Sympathikus#Selektive .CE.B11-Blocker|Pharmakologie und Toxikologie: Sympathikus-Selektive α1-Blocker}}
{{Wikibooks|Lunge: Anatomie#Anatomie Aufbau|Anatomie der Lunge}}
{{Wikibooks|Lunge: Anatomie#Feinbau|Anatomie der Lunge}}
http://de.wikibooks.org/wiki/Pharmakologie_und_Toxikologie:_Sympathikus#Selektive_.CE.B11-Blocker
→ ''Hauptartikel: [[K.-o.-Tropfen]]''
→ ''Hauptartikel: [[Mukoviszidose]] ''
{{AWMF|http://www.uni-duesseldorf.de/AWMF/ll/nvl-003l.pdf|COPD|S3|Nationalen Programm für Versorgungs-Leitlinien von Bundesärztekammer, AWMF und KBV|02/2010}}
{{AWMF|http://www.uni-duesseldorf.de/AWMF/ll/005-003.htm|Diagnostik und Therapie des Karpaltunnelsyndroms|S3|Deutschen Gesellschaft für Orthopädie und Orthopädische Chirurgie|11/2006}}
[[Vorlage:AWMF]]
{{AWMF|http://www.uni-duesseldorf.de/AWMF/ll/021-013.htm|Gastroösophageale Refluxkrankheit -Ergebnisse einer "Evidenz"-basierten Konsensuskonferenz|S3|Deutschen Gesellschaft für Verdauungs- und Stoffwechselerkrankungen|2005}}
{{AWMF|http://www.uni-duesseldorf.de/AWMF/ll/017-050.htm|Riechstörungen: Leitlinie zur Epidemiologie, Pathophysiologie, Klassifikation, Diagnose und Therapie|S2|Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie|05/2007}}
[http://tools.wikimedia.de/~daniel/WikiSense/CategoryIntersect.php CAT SCAN]
<ref name="BGIA GESTIS">{{GESTIS|Name=4-Aminosalicylsäure|ZVG=492363|CAS=65-49-6|Datum=06.02.2008}}</ref>
<ref name="MERCK Index">The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals, 14. Auflage (Merck & Co., Inc.), Whitehouse Station, NJ, USA, 2006; ISBN 978-0-911910-00-1</ref>
<ref name="Trental">[http://products.sanofi-aventis.us/trental/trental.pdf ''Englische Fachinformation für Trental<sup>®</sup> (pentoxifylline tablets) von Sanofi-aventis U.S. – Stand der Information: Oktober 2007'']</ref>
<ref>Holmes B, et al., ''Piperacillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use''. Drugs. 1984 Nov;28(5):375-425 PMID 6391888</ref>
<ref>Martin, J.G., et al., ''In vivo airway reactivity: predictive value of morphological estimates of airway smooth muscle''. Can. J. Physiol. Pharmacol. '''70''', 597-601, (1992) PMID 1498724</ref>
<ref>Mei, L., et al., ''Pharmacologic comparison of selected agonists for the M1 muscarinic receptor in transfected murine fibroblast cells (B82)''. J. Pharmacol. Exp. Ther. '''256''', 689, (1991) PMID 1704434</ref>
<ref>Blosser S, et al., ''Effects of increased bronchial blood flow on airway morphometry, resistance, and reactivity.''J Appl Physiol. (1994) Apr;76(4):1624-9. PMID 8045841</ref>
<ref>In Bezug auf ihre Gefährlichkeit wurde die Substanz von der EU noch nicht eingestuft, eine verlässliche und zitierfähige Quelle hierzu wurde noch nicht gefunden.</ref>
== Einzelnachweise ==
<references />
siehe auch [[WP:RC#Verlinkung auf Synthesevorschriften]]
<ref name="BGIA GESTIS">{{GESTIS|Name= |ZVG=|CAS= |Datum= }}</ref>
<ref name="ChemIDplus">{{ChemID|}}</ref>
<ref name="sigma">[ Sicherheitsdatenblatt für ''' ''' – Sigma-Aldrich 30.12.2007]</ref>
<ref name="Merck">[ Sicherheitsdatenblatt für ''' ''' – Merckbiosciences 14.01.2008]</ref>
<ref name="RÖMPP Online">{{Literatur|Hrsg=Thieme Chemistry|Titel=RÖMPP Online - Version 3.1|Verlag=Georg Thieme Verlag KG|Ort=Stuttgart|Datum=2008}}</ref>
<ref name="Ph. Eur. 5">{{Literatur|Hrsg=Europäische Arzneibuch-Kommission|Titel=EUROPÄISCHE PHARMAKOPÖE 5. AUSGABE|Band=5.0 - 5.7|Datum=2006}}</ref>
{{löschen|Durch [[:Bild:]] ersetzt}}
{{NowCommons|Apixaban.png}}
{{subst:unsigned|Benutzername oder IP des Benutzers|Uhrzeit, Datum des unsignierten Beitrags}}
{{Wikibooks|Biologie für Mediziner}}
http://de.wikibooks.org/wiki/Schilddr%C3%BCse:_Biochemie#Iod_Transport_in_die_SD-Zelle:_Natrium-Iodid_Symporter
<ref name="Legalon">Fachinformation aus dem [[Arzneimittel-Kompendium der Schweiz]] für
''Legalon<sup>®</sup> SIL'' von Max Zeller Söhne – Stand: Juni 2007</ref>
{{cite journal |author=Søgaard U, Michalow J, Butler B, ''et al'' |title=A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR 12909 in healthy subjects |journal=International clinical psychopharmacology |volume=5 |issue=4 |pages=237-51 |year=1990 |pmid=2150527 |doi=}}
Blabla<ref>''[http://cocaine.org/gbr12909/antidepressant.html The dopamine inhibitor GBR 12909:selectivity and molecular mechanism of action]'' Eur J Pharmacol 1989 Aug 3; 166(3):493-504</ref>
<ref>[http://www.jneurosci.org/cgi/reprint/16/23/7416.pdf ''Differential Reinforcing Effects of Cocaine and GBR-12909:Biochemical Evidence for Divergent Neuroadaptive Changes in the Mesolimbic Dopaminergic System'']The Journal of Neuroscience, December 1, 1996, 16(23):7416–7427(PDF)</ref>
<ref name="Merck">[http://www.merck-chemicals.com/is-bin/INTERSHOP.enfinity/WFS/Merck-International-Site/de_DE/-/USD/ShowDocument-Protected?ProductAttachmentUUID=8Oib.s1Obg8AAAEWlyJwbT4w&ProductUUID=zp.b.s1OdP0AAAEWz0twbT2. Sicherheitsdatenblatt für Morphine hydrochloride – Merck 29.12.2007]</ref>
[http://www.merck-chemicals.com/is-bin/INTERSHOP.enfinity/WFS/Merck-International-Site/de_DE/-/USD/ShowDocument-Protected?ProductAttachmentUUID=8Oib.s1Obg8AAAEWlyJwbT4w&ProductUUID=zp.b.s1OdP0AAAEWz0twbT2.]
<ref name="Ph. Eur.">[ Safety Data Sheet for '' '' – European Pharmacopoeia (Ph. Eur.) ]</ref>
== Quellen ==
<references />
== Weblinks ==
[http://www.nzz.ch/nachrichten/zuerich/aktuell/aus_leidenschaft_fuer_das_detail_1.571859.html Crazy-Chemist in der NZZ]
{{Infobox ICD
| BREITE =
| 01-CODE = C07
| 01-BEZEICHNUNG = Bösartige Neubildung der Parotis
| 02-CODE = C08
| 02-BEZEICHNUNG = Bösartige Neubildung sonstiger und nicht näher bezeichneter großer Speicheldrüsen<br />[[ICD-O]] M8200/3<br /> Adenoidzystisches Karzinom
}}
{{Infobox ICD
| BREITE =
| 01-CODE = B60.8
| 01-BEZEICHNUNG = Mikrosporidiose
}}
{{Infobox ICD
| BREITE =
| 01-CODE = '''K11.5'''
| 01-BEZEICHNUNG = '''Sialolithiasis'''<br />
Sialolith<br />
Speichelstein
}}
{{Infobox ICD
| BREITE =
| 01-CODE = '''G24.0'''
| 01-BEZEICHNUNG = '''Arzneimittelinduzierte Dystonie'''<br />
Dyskinesia tarda
}}
{{Infobox ICD
| BREITE =
| 01-CODE = '''M54'''
| 01-BEZEICHNUNG = '''Rückenschmerzen'''
| 02-CODE = M54.2
| 02-BEZEICHNUNG = Zervikalneuralgie
}}
G24.0 Arzneimittelinduzierte Dystonie
Dyskinesia tarda
{{Infobox ICD
| BREITE =
| 01-CODE = '''K14.1'''
| 01-BEZEICHNUNG = '''Lingua geographica'''<br />
Exfoliatio areata linguae<br />
Glossitis migrans benigna
}}
[[Celsius|°C]]
[[Grad Celsius|°C]]
{| class="wikitable float-right"
|-
! colspan="2" style="background:#DEFFAD"| Dosimetermethode nach ATS 200
|-
! <small>Stufe</small> || <small>Verneblungszeit</small> || <small>Atemzüge</small> || <small>Konzentration</small> || <small>Vernebelte Aerosolmenge</small> || <small>Kumulative Aerosolmenge</small>
|-
| 1. Stufe || 0,6 || 5 || 0,0625 || 2,8 || 2,8
|-
| 2. Stufe || 0,6 || 5 || 0,25 || 11,3 || 14,1
|-
| 3. Stufe ||0,6 || 5 || 1 || 45,0 || 59,1
|-
| 4. Stufe || 0,6 || 5 || 4 || 180,0 || 239,1
|-
| 5. Stufe || 0,6 || 5 || 16 || 720,0 || 959,1
|-
|}